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 PRESENTACION 
                                                                                                                                                 PRESENTACION 
 
   El desarrollo de antibióticos ha permitido combatir distintas enfermedades infecciosas 
durante el siglo XX, como la tuberculosis, neumonía, fiebre tifoidea o meningitis. 
Desafortunadamente, el uso inadecuado de los antibióticos ha conducido a la aparición de 
cepas resistentes a distintitos fármacos, y actualmente se considera uno de los principales 
problemas de salud pública a nivel global del siglo XXI. 
   Los avances recientes en nanotecnología han permitido la preparación de distintos 
nanomateriales, como nanopartículas, con un amplio espectro de propiedades. Diversos 
sistemas basados en nanotecnología se han propuesto como herramientas eficaces para el 
control de microorganismos resistentes a antibióticos. En esta línea, nosotros hemos 
propuesto el uso de bacterias psicrófilas para la preparación de nanopartículas de plata 
(AgNPs) a baja temperatura, que permitan controlar el crecimiento de bacterias patógenas. En 
concreto hemos evaluado cuatro bacterias psicrófilas en la obtención de AgNPs bajo diferentes 
condiciones, como la presencia de NaCl o la temperatura. La actividad antimicrobiana de las 
nanopartículas obtenidas ha sido evaluada tanto en bacterias Gram-positivas como en Gram-
negativas.  
   Otro tipo de nanomaterial empleado en este trabajo, son los nanoclústeres de plata 
estabilizados por oligonucleótidos (DNA-AgNCs), los cuales presentan propiedades 
fluorescentes que pueden ser moduladas por la selección del oligonucleótido empleado. Estos 
derivados se han utilizado ampliamente en el desarrollo de sensores, pero su uso como 
agentes antimicrobianos no ha sido descrito.  
   Por otra parte, oligonucleótidos modificados con una molécula fluorescente han sido 
evaluados en terapia fotodinámica contra bacterias patógenas.  
   Finalmente, en un proyecto en colaboración con el Centro Nacional de Biotecnología (CNB) se 
ha explorado el uso de nanopartículas de oro modificadas con oligonucleótidos para controlar 
la expresión del gen p21 en células T.  
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 PRESENTACION 
 
Por tanto, los tres objetivos principales de esta tesis doctoral son: 
 
1. Preparación de AgNPs utilizando extractos de bacterias obtenidas en la Antárctica y su 
evaluación biológica.  
2. Evaluación de DNA-AgNCs como nuevos agentes antimicrobianos. 
3. Desarrollo y evaluación de conjugados de oligonucleótidos en terapia fotodinámica.  
Por otra parte, se han iniciado un proyecto donde se explora otro uso de nanomateriales en 
biomedicina como es: 
4. La regulación de p21 mediante nanopartículas de oro modificadas con oligonucleótidos. 
 
   En esta tesis doctoral se han utilizado cuatro cepas de bacterias psicrófilas obtenidas de la 
Antártica (Psychrobacter sp., Aeromonas salmonicida, Pseudomonas veronii, and Yersinia 
kristensenii), las cuales no han sido empleadas anteriormente en la preparación de AgNPs. Las 
nanoestructuras obtenidas han mostrado una buena actividad antimicrobiana contra bacterias  
Gram-positivas (Staphylococcus epidermidis) y Gram-negativas (Escheriachia coli and Klebsiella 
pneumonia).  
 
   La actividad antimicrobiana de DNA-AgNCs ha sido evaluada contra E. coli y S. epidermidis y 
sorprendentemente, la actividad depende de la secuencia empleada en la estabilización de los 
nanoclústeres de plata. La secuencia más activa ha sido utilizada en la preparación de un 
trímero que ha mostrado una actividad superior al monómero.  
   Para la última estrategia evaluada para controlar el crecimiento bacteriano se han preparado 
conjugados de oligonucleótidos con moléculas fluorescentes, que al ser excitadas por una luz 
inducen la muerte de las bacterias a baja concentración (0.750 and 1.5µM). En este caso el 
estudio se llevó a cabo en E. coli, P. aeruginosa y S. aureus y también se ha observado que la 
actividad depende en gran parte de la secuencia empleada.  
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 ABSTRACT 
                                                                                                                                                        ABSTRACT 
   In this thesis, we have initiated four research projects. Three of them related to the 
development and evaluation of nanomaterials as antimicrobials. The fourth one is devoted to 
the assessment of gold nanoparticles modified with oligonucleotides as regulators of p21 
expression. 
   The first project has been carried out at the Universidad Autónoma de Madrid and deals with 
the preparation of silver nanoparticles (AgNPs) using broths from bacteria and their evaluation 
as antimicrobials. Particularly, four psychrophilic bacteria isolated from Antarctica have been 
evaluated. Different conditions were assessed, including the addition of NaCl and incubation 
temperatures. The AgNPs obtained were characterized and their antimicrobial properties 
evaluated against Gram-negative and Gram-positive bacteria.  
   We also have evaluated the antimicrobial properties of silver nanoclusters stabilized by DNA 
(DNA-AgNCs), which are novel fluorescent materials. After testing 9 oligonucleotides with 
different sequence and length we found that the antibacterial activity depends on the 
sequence of the oligonucleotides employed. The sequences tested yielded fluorescent AgNCs, 
which can be grouped in blue, yellow and red emitters. Interestingly, blue emitters yielded 
poor antibacterial activity whereas yellow and red emitters afforded an activity similar to 
AgNO3. Finally, we prepared a trimeric structure containing the sequence that afforded the 
best antimicrobial activity, which inhibited the growth of Gram positive and negative bacteria 
in the sub-micromolar range. 
   In the third project, we demonstrated that oligonucleotides modified with a fluorescent dye 
(HEX) can be used in photodynamic therapy to kill bacteria. Interestingly, the sequence of the 
oligonucleotide employed modulates the antimicrobial activity of the system.  
   The last project has been done in collaboration with the Centro Nacional de Biotecnología 
(CNB) and the preliminary results of the regulation of p21 with modified gold nanoparticles are 
presented. P21 is involved in cell senescence and replication, and its regulation can be done 
using different oligonucleotides, such as antisense and siRNAs. However, the translocation into 
the cells of nucleic acids is not easy and transfection systems are required. In this case, 
oligonucleotides were conjugated to gold nanoparticles (AuNPs) and used in T-cells. The results 
suggest that the approach employed is valid although further optimization is required.  
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
1.   INTRODUCTION 
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1 INTRODUCTION 
 
                                                                                                                                   1.   INTRODUCTION 
1.1. Nanomedicine 
   Nanotechnology is the engineering and control of organic and inorganic materials generally in 
the 1-100 nm dimension range, where the materials can present new or enhanced 
properties1,2. A subarea of nanotechnology is nanomedicine, which exploits the properties of 
nanomaterials in biomedicine and includes, but is not limited to, the development of 
nanoparticles (NPs), nanofibers, and nanopatterned surfaces for different applications such as, 
drug delivery3, regenerative medicine4 , imaging5 and sensing6. Nowadays, nanomedicine is a 
promising research area that can provide alternative solutions to the detection and treatment 
of a variety of maladies, including autoimmune diseases7, vascular diseases8 and cancer9-11.  
   Among the different materials employed in nanomedicine, NPs are the most widely used due 
to the ease of preparation and modification, even at large scale. This kind of nanostructures 
can be obtained from a variety of compounds such as phospholipids12 , lactic acid13 , chitosan14, 
dextran15 , silica16 and a diversity of metals, such as: gold17 , nickel18 , silver19 , iron oxide20 , zinc 
oxide21 , gadolinium22 and titanium dioxide23. Each NP has unique properties that make it ideal 
for a given application. In our case we have focused our work mainly in silver derivatives due to 
their antimicrobial properties discussed below. 
 
1.2. Silver and Silver Nanoparticles 
   Silver is one of the first metals employed in medicine due to its antimicrobial properties. In 
this sense, ancient Macedonians were probably the first to use silver derivatives to improve 
wound healing. Similar applications where implemented in Greece, Rome, and Phoenicia 
where silver was used extensively to control infections and prevent spoilage of water and 
food24.  
   A common application of silver uses silver nitrate to prevent infections and promote healing 
in topical burns or the eye infection of newborns. However, it has to be employed at low 
concentrations (0.5-1%) due to its toxic effects25,26.  
   On the other hand, metallic NPs have been around us also since ancient times, particularly in 
the elaboration of stained glass. One of the most famous examples is the “Lycurgus Cup”, 
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dating back to the 4th century A.D. The Lycurgus Cup, as well as the medieval cathedral 
windows, contain metallic NPs that bring their unique optical properties to produce 
aesthetically pleasing colours. Particularly, gold and silver nanoparticles (AgNPs) within the 
glass are responsible of the brilliant red and green colors that contribute to the light scattering 
phenomena observed (Fig 1.1). In addition, the colour of the glass changes depending whether 
the light is reflected on or transmitted through the glass. This colour change must have 
fascinated the ancient people during that time.  
 
 
 
 
 
 
 
 
 
 
Figure1.1. The “Lycurgus Cup” and “ Cathedral Window” (Saint Chapelle in Paris) older applications of nanotechnology. 
 
   Although the applications of silver for biomedical purposes and AgNPs as glass stain have 
been around us for centuries, the use of AgNPs to treat diseases is more recent. In 1889, M.C. 
Lea, reported the synthesis of a citrate stabilized AgNPs (known as colloids in the past), which 
diameter was between 7 and 9 nm. Later on, in 1897, different formulations of AgNPs were 
manufactured and used for medical applications, such as Collargol, Argyrol and Protargol27. 
Since then, multiple medical applications of AgNPs have been reported, due to their unique 
optical, electrical and thermal properties. 
   These properties are mainly due to the collective excitation of the conductive electrons 
(plasmons), which in the particles are localized in the surface28. When the light interacts with 
the particles it excites the surface plasmons, causing a coherent oscillation of the conduction 
band of electrons, known as surface Plasmon resonance (SPR). This effect can be observed in 
the visible region of the spectrum and dependents on the particle composition, size, shape, 
and surrounding dielectric environment29. It is worth mentioning that AgNPs are able to absorb 
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and scatter light better than other metallic NPs (e.g. Au)30,31 making them one of the most 
interesting nanomaterials for optical applications. 
   Due to the properties mentioned above the applications of AgNCs are mainly focused in 
sensing of different materials (nucleic acids32, metal ions33,34, organic molecules35 and 
proteins36) and to control the growth of unhealthy bacteria. In this regard, AgNPs have some 
advantages compared to other silver derivatives such a low toxicity to human cells37, probably 
due to the slow release of Ag+38and the improved interaction with bacterial cells39-42. For these 
reasons, AgNPs are currently been used as an additive to prevent bacteria growth in multiple 
elements, such as in apparel, footwear, paints, wound dressing, appliances, cosmetics and 
plastics43. 
 
1.2.1. Synthesis of AgNPs 
   AgNPs can be obtained by different strategies than can be grouped in three different and 
complementary approaches, known as 1).Chemical methods, 2). Physical methods and 3). 
Biological methods.  
   1). Chemical methods: In this case a silver salt is reduced to yield the final AgNP, which can 
be carried out in different ways involving chemical44,45, electrochemical46, and pyrolytic 
reductions47. 
   2). Physical methods: By contrast, physical methods do not involve chemicals and usually 
have fast processing time. Such methods include physical vapor condensation48, arc-
discharge49, energy ball milling method50, and direct current (DC) magnetron sputtering51. 
   3). Biological methods: In the biological synthesis of AgNPs, the toxic reducing agents and 
stabilizers are replaced by non-toxic molecules (proteins, carbohydrates, antioxidants) 
produced by living organisms, including bacteria52, fungi53, yeasts54, and plants55. In these cases 
the reduction might involve enzymatic (e.g., NADPH reductase) processes56 as well as a variety 
of biomolecules (e.g. aminoacids, polysaccharides and vitamins)57. 
   The use of organisms to generate AgNPs presents some advantages versus the chemical and 
physical methods. Particularly, the lack of toxic chemicals, which are replaced by extracts from 
plants or large variety of microorganism58, the easy set-up required, which can be scaled-up, 
make the whole process very cost-effective59,60.  
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1.2.2. Biosynthesis of AgNPs 
   The first intercellular synthesis of AgNPs by bacteria was reported in 1999 where 
Pseudomonas stutzeri AG259 was employed61. In this case particles with a diameter below 200 
nm were obtained. Since then, different bacteria have been employed to obtain this type of 
nanostructures62,63 . 
   The generation of AgNPs by microorganisms implies that they can tolerate metal ions at high 
concentrations. Then, through different mechanisms the bacteria are able to transform the 
salts into the metallic NPs64. 
   Extremophiles seem to be good candidates as NPs producers, since these microorganisms 
have been adapted to grow in harsh conditions such as extreme pH, temperature, salinity and 
absence of oxygen65,66. 
   Among this group, psychrophiles are extremophilic bacteria that live in very cold 
environments (-20 °C to +10 °C) and usually at high salt concentration67. A couple of reports 
have shown the capabilities of this family of bacteria in the production of AgNPs68,69. 
Interestingly, Ramanathan and co-workers were able to control the shape of the AgNPs using 
Morganella psychrotolerans70. S. Shivaji and co-workers employed cell-free culture 
supernatants of five psychrophilicbacteria  (Pseudomonas antarctica, Pseudomonas 
proteolytica, Pseudomonas meridiana, Arthrobacter kerguelensis and Arthrobacter 
gangotriensis) and two mesophilic bacteria (Bacillus indicus and Bacillus cecembensis) to 
synthesize AgNPs. In this case the size of the AgNPs ranged from 6 to 13 nm and were stable 
for 8 months when stored in the dark69. 
 
1.2.3. Why AgNPs? 
   The introduction of antibiotics is one of the most important medical interventions with 
regard to reducing human morbidity and mortality71. The penicillin was discovered by Sir 
Alexander Fleming in 1928, and since then, a variety of antibiotics have been developed to 
treat a myriad of bacterial infections. Unfortunately, in the past decade the number of 
antibiotics to which bacteria have developed resistance has increased considerably. As a 
consequence, some agents are no longer useful for the treatment of infections and even 
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several strains are becoming resistant to more than one antibiotic72. For these reasons there is 
a great urgency to develop novel antibiotics73. 
   The specific target for most antibiotics are the cell wall synthesis (e.g. Penicillin74, 
Cephalosporins75 and Carbapenems76), the protein or RNA synthesis (Tetracyclines 77and 
Rifamycins78), the DNA replication (Quinolones79 and Metronidazole80) or the energy 
metabolism. The activity of antibiotics depend on the strain tested, but two big groups are 
stablished related to the cell wall structure, Gram-positive and Gram-negative.  
   Most prokaryotes have a rigid cell wall, which is an essential structure that protects the cell 
protoplast from mechanical damage and from osmotic rupture or lysis. In the Gram-positive 
bacteria (those that retain the purple crystal violet dye when subjected to the Gram-staining 
procedure), the cell wall consists of cytoplasmic lipid membrane, with a thick peptidoglycan 
layer, lipoteichoic acids, peptidoglycans and a small periplasmic space. In the Gram-negative 
bacteria, which do not retain the crystal violet, the cell wall is composed of a cytoplasmic 
membrane with a thin peptidoglycan layer and larger periplasmic space. In addition they have 
an outer membrane containing lipopolysaccharides and porins81,82(Fig 1.2).  
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Figure1.2. The structure of the cell wall in A). Gram-negative  and, B). Gram-positive bacteria (adapted from 83-85). 
 
   Bacterial cell walls are unique structures that are not present in mammalian cells, and 
therefore serve as ideal targets for antimicrobial drugs. Understanding the molecular basis of 
interaction and effect of antibiotics in bacterial membranes is key to design new drugs to 
overcome the current resistance86,87.  
   There are different mechanisms that bacteria can use to develop resistance to antibiotics. For 
example, plasmid-mediated enzyme production of proteins that inhibit the activity of 
antibiotics (e.g. aminoglycosides or penicillins), alteration of the target site of antibiotics, such 
as mutations in the Penicillin-Binding Proteins (PBPs), or the alteration in metabolic pathways 
to circumvent the drug activity 88,89(Fig 1.3). 
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Figure1.3. Various mechanisms that bacteria use to resistance to antibiotics
90
. 
 
 
   However, the use of silver derivatives and particularly AgNPs seems to reduce the 
development of bacteria resistance compared to traditional antibiotics, due to the low number 
to reported cases despite its widespread use, making them ideal candidates for the 
development of novel nanoantibiotics 91-94.  
 
1.2.4. Silver nanomaterials-based antimicrobial: mechanism of action 
   AgNPs, compared to silver ions and standard metallic silver, are effective in the broader 
spectrum of microorganisms (bacteria, antibiotic resistant strains, fungi and virus)95-98. 
However, the mechanism of action is not completely clear and different processes seem to be 
involved. Particularly, AgNPs interact with the cell wall increasing its permeability leading to 
osmotic unbalances and uncontrolled transport through the cytoplasmic membrane, which 
cause the death of the bacteria99-101. In addition, after penetrating the bacteria, AgNPs can 
react with proteins and DNA99-103. AgNPs modulate the phosphotyrosine profile of putative 
bacterial peptides that can affect cellular signaling, with leads to growth inhibition in 
bacteria104. 
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One of the most established antimicrobial mechanism of silver derivatives is related with the 
generation of reactive oxygen species (ROS), which are generated on different oxidized 
molecules, such as O2, H2O2, OH
-, and NO105,106 due to the susceptibility of oxygen to get 
reduced. This kind of species are very reactive and can attack different molecules including 
lipids107 proteins108, and nucleic acids109 . ROS are produced as a by-product in every organism 
during oxidative processes such a respiration and under regular conditions the organisms have 
efficient ways to neutralize them. Indeed, in Escherichia coli up to 87% of the H2O2 is generated 
along the respiratory chain110. However, when there is an increase of these reactive molecules 
significant damage can be produced leading to cell death. This is the case when some 
antibiotics111 or silver derivatives, such as, AgNPs112 and silver nanoclusters (AgNCs)113 are 
employed. 
The detection of ROS, including, super oxide radical, hydrogen peroxide, singlet oxygen, 
hydroxyl radical and peroxyl radical, can be done easily with their specific fluorescent probes, 
hydroethidine (HE), 2´,7´-dichlorodihydrofluorescin (DCFH), 9,10-dimethylanthracene (DMA), 
1,3-cyclohexanedione (CHD) and, dipyridamole114 respectively. One of the most commonly 
used probe is 2´,7´-dichlorodihydrofluorescin diacetate (DCFH-DA), which acetyl groups can be 
removed by esterases inside the cells to yield 2´,7´-dichlorodihydrofluorescin (DCFH). Then, in 
the presence of hydrogen peroxide it is oxidized to the highly fluorescent 2´,7´-
dichlorofluorescin (DCF) (Fig 1.4).  
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Figure1.4. Fluorescent probe employed to detect ROS. 
 
   On the other hand, several studies have shown that AgNPs can be toxic in mammalian cells, 
thus, in the last years several groups are working on strategies to reduce the toxicity of 
AgNPs115-117. Some of the methods developed involve the use of drug delivery systems, which 
when used in combination with antibiotics can reduce the toxicity of both compounds and 
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enhance their antibacterial activity118,119. It is important to mention that some factors that 
control the activity of AgNPs are their size120,121and shape122. In this sense, AgNPs of 25 nm 
have shown higher antibacterial activity than smaller ones123. Regarding their shape, 
triangular124, spherical, rod and flower shaped nanostructures have been evaluated where the 
spherical structures turned to be the less active125.  
 
1.3. Metal Clusters 
   As mentioned before metallic NPs have different properties compare to the bulk material. 
Interestingly, even within the nanoscale new properties can appear when metallic 
nanostructures have sizes below 2 nm, such as fluorescence. In this case, they are known as 
nanoclusters (NCs) and are composed of just few atoms of the corresponding metal125-129. 
   Fluorescent structures are very interesting materials with applications in different disciplines 
such as, nanotechnology, biotechnology and medical research. The fluorescent systems 
currently employed can be divided in three major groups: organic molecules130, fluorescent 
proteins131 and nanocrystals132. Despite their good fluorescent properties all of them have 
some drawbacks (e.g. photobleaching, large size, toxicity) and for this reason novel fluorescent 
materials are welcome. In this regard, metal NCs are promising new fluorescent materials, due 
to their small size, excellent photostability and low toxicity. 
   NCs can be obtained from their corresponding salts through radiolytic133, chemical134, or 
photochemical reduction135. However, in order to prevent their degradation and control their 
size, capping agents are required such as zeolites136, PAMAM137, PMMA138, polyacrylate139, poly 
(NIPAM-AA-HEA) microgels140, sugar molecules141, peptides142mercaptosuccinic acid143, lipoic 
acid144 and other thiolated derivatives145, and DNA146.  
   Due to the fluorescent properties of NCs multiple applications have been developed for the 
detection of different molecules147 such as, ions148, small molecules149, nucleic-acid150, proteins, 
even in cell models151. 
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1.3.1. DNA-Stabilized  Silver Nanoclusters 
   Among the different stabilizing agents employed in the preparation of AgNCs, 
oligonucleotides can provided additional features to the nanostructures, which have motivated 
lot of research in this area. Particularly, the fluorescent properties of DNA-templated silver 
nanoclusters (DNA-AgNCs) can be tuned by the selection of the oligonucleotide employed. In 
this sense, it is possible to prepare emitters from the blue to the near-infrared region just by 
the selection of the proper oligonucleotide. Additionally, the fluorescence properties of DNA-
AgNCs are very sensitive to the environment and for this reason they have been employed in 
the preparation of multiple sensing systems for small molecules152, ions153 , enzymes154 and 
nucleic acids155 . 
 
1.4. Gold Nanoparticles 
   Another interesting metallic nanostructures are those derived from gold. Gold possesses 
interesting physical and chemical properties in both the macroscopic and microscopic states. 
At the macroscopic scale gold is known for its unique yellowish color, its chemical stability, 
metallic behavior and high redox potential. On the other hand, at the nanoscale metallic gold is 
less stable, semiconductor and has a reddish colour due to 1) the high ratio of surface atoms vs 
bulk atoms156, 2) the quantum effects  that explain the change from metallic to semiconducting 
character of very small particles157 , and 3) the electromagnetic confinement of electrons158. 
   Gold nanoparticles (AuNPs) can be obtained easily using different approaches such as the 
Turkevich and Frens method159, the Brust method160, the microemulsion method161,162, the 
seeding method163, the Zhong method164,the Xia method165 as well as biological methods 
where microorganisms166, enzymes167, and plants or plant extracts are employed168.  
   AuNPs have been used in biomedicine in a variety of applications169 such as: diagnostics and 
sensing170-172, imaging173-175, photothermal therapy176 and drug delivery177-179. In this thesis we 
have employed them as carriers of different nucleic acids to control the expression of the p21 
gene.  
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1.5.  Photodynamic Therapy for the treatment of Infectious Diseases  
   Historically, phototherapy began in Ancient Egypt, Greece, and India180 , where light was 
employed to treat skin diseases, such as psoriasis181, but disappeared for many centuries and 
was rediscovered at the beginning of the twentieth century. Photodynamic therapy (PDT) is a 
form of phototherapy that requires three key components: a photosensitizer (PS), a light 
source, and oxygen. PS are light-sensitive molecules that can be excited with light to produce 
ROS in the presence of oxygen. These ROS are generated during PDT through two types of 
reactions182. Type I involves electron/hydrogen transfer directly from the PS, producing ions, or 
electron/hydrogen abstraction from a substrate molecule to form free radicals. Type II 
produces the electronically excited and highly reactive state of oxygen known as singlet 
oxygen183 (Fig 1.5). 
 
 
 
Figure1.5. Schematic illustration of a typical photodynamic reaction. 
 
     
   PDT is used clinically to treat a wide range of diseases, such as infectious diseases, cancer, 
and even psychosis with very low toxicity. 
   Recently, PS for antimicrobial PDT or PACT on antibiotic resistance bacteria have been 
reported 184-186. One of the advantages of PACT is that antibiotic resistant and susceptible 
bacteria can be killed effectively. Moreover, it is possible to selective target the pathogenic 
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bacteria using a targeting moiety such as an aptamer187,188 improving its efficacy and reducing 
the side effects.  
   Multiple PS have been employed against Gram-positive and Gram-negative bacteria such as 
methylene blue189, porphyrins190, cyanine191 as well as fluorescein derivatives, such as 
erythrosine and Rose Bengal192. For instance, Rose Bengal at 50 µmol/l excited with blue light 
was employed to inhibit the growth of Enterobacteriaceae strains . 
   In this thesis we plan to evaluate oligonucleotides modified with PS as antimicrobials. 
 
 
1.6. Nucleic Acids For Gene Regulation 
   The central dogma of molecular biology, “DNA makes RNA and RNA makes protein” was first 
stated by Francis Crick in 1956193. Since then, great efforts have been focused on sequencing 
the information encoded in the DNA that leads to the generation of proteins. However, 
nowadays it is known that the central dogma of molecular biology is involved only in a small 
section of the information encoded in the DNA and most of the information encoded deals 
with regulation194,195. 
   It is known that many diseases are related with the genes, from a mutation in a gene that can 
lead to an inactivated or aberrantly expressed protein, to a dysregulation in their expression, 
which can increase or reduce the amount of the proteins present in the cell. In this regard, 
regulatory RNAs, which control the expression of the genes, are been evaluated as biomarkers 
for the detection of diseases and even as drug targets for their treatment196. In order to control 
their activity different strategies involving oligonucleotides have been developed as detailed 
below. 
 
1.6.1. Antisense therapeutics 
   Antisense oligonucleotides (AS-ODNs) are short oligonucleotides (18-25 bases) designed to 
bind specific RNA sequences inside cell. The ODN-RNA duplex generated then prevents protein 
translation by RNase H, which decompose the RNA, or by preventing the ribosomal access 
and/or assembly197. The use of As-ODNs to treat diseases, has multiple hurdles, such as the 
delivery198, stability199 and off-target effects200,201. Additionally, the uptake and sequestration of 
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AS-ODNs in the reticuloendothelial system and intracellular sequestration by oligo-protein 
complexes and phagolysosomes202 can reduce its activity. Most of these problems have been 
addressed using different chemical modifications in the phosphodiester back bone, the 
nucleobase and/or the sugar moiety, which can increase the affinity and specificity of AS-ODNS 
for RNA target sequences 203 (Fig 1.6).  
   The most widely used modifications are the 2´O-methyl and phosphorothioates (2´OMePS), 
which exhibit improved stability and increased cellular uptake204,205. 
   These improvements have led to the development of novel therapeutic compounds based on 
oligonucleotides such as Fomivirsen206(marketed as Vitravene),  which was approved by the 
FDA in 1998 for treatment cytomegalovirus retinitis (CMV) and Mipomersen207 (marketed as 
Kynamro) for the treatment of homozygous familial hypercholesterolemia (HoFH) and also 
pegaptanib sodium injection208 (marketed as Macugen), an anti-angiogenic for the treatment 
of neovascular age-related macular degeneration (AMD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.6. An overview of different chemical modifications of antisense oligonucleotids (AONs); B=nucleobase205. 
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1.6.2.  RNA interference (RNAi) 
   RNAi is an intracellular defense system which historically was called “co-suppression, post 
transcriptional gene silencing” (PTGS) and quelling209. In the RNAi process, long double-
stranded RNAs can trigger the cleavage activity of the intracellular enzyme, Dicer, leading to 
small RNA duplexes of 19-21 nucleotides, known as small interfering RNAs (siRNA). Then, a 
protein complex (RISC), binds the siRNA duplex and removes one of the strands of the duplex, 
known as passenger. At this point the RISC complex is activated and will use the guide strand to 
find the complementary sequence in the mRNA present in the cytoplasm, which is cut in two 
pieces by the endonuclease activity of the RISC complex210 (Fig 1.7). The process can be 
repeated by the RISC complex multiple times leading to an effective reduction of the protein 
expressed in the target mRNA. Due to the high selectivity and activity of the RNAi process it is 
currently being assessed as a novel therapeutic by targeting the expression of proteins 
involved in different diseases such as cancer, Crohn’s disease, macular degeneration or 
hypercholesterolemia. However, one of the main limitations of this technology in humans is 
the delivery, which can be improved using different carriers. 
 
 
Figure 1.7. Schematic representation of the mechanism of RNA interference. 
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-MiRNAs 
   MiRNAs are 20-24 nucleotide long RNA structures that bind to the 3´ UTR (untranslated 
region) of target mRNAs, leading to translational repression or mRNA degradation. MiRNA have 
a key role in proliferation, development, differentiation, apoptosis, angiogenesis, and immune 
response and other normal physiological functions. It is proved that miRNAs are important 
regulators of gene expression in eukaryotes211-213. To date it have been reported, around 
15,000 miRNAs in eukaryotic organisms and the number is increasing every day. In humans 
around 30% of protein coding genes are controlled by miRNAs214. MiRNAs are involved in the 
pathogenesis of several human diseases including cancer215, immune216, cardiovascular217 and 
neurological disorders218 and can be found almost in every fluid. For these reasons, miRNAs are 
very attractive biomarkers for different human diseases. 
   MiRNAs are generated by RNA polymerase II or III from the stem loop that transcribed        
pri-mRNA pathway or an alternative miRtron pathway. Recently, miRtron pathway has been 
found in mammals, drosophila and nematodes. The miRtron pathway involves the Drosha-
DGCR8 complex, which leads the formation of pre-miRs of 70nt length, from their 
corresponding pri-miRs. Then pre-miRNAs are exported to the cytoplasm through Exportin-5-
Ran complex, and then cleaved by Dicer yielding 20bp mi-RNA:mi-RNA duplexes. The miRNA 
induced silencing complex (miRISC) is formed by one of the strands of the duplex and a protein 
complex know as RISC, which is able to control the expression of the genes through 
translational repression or mRNA cleavage, similar as in the case of RNAi. 
 
1.6.3.  p21 Gene  
   In this thesis we plan to use different oligonucleotides conjugated to AuNPs to control the 
expression of the p21 gene. The corresponding protein plays multiple biological roles such as a 
cell-cycle regulator in response to DNA damage, regulator of transcription, senescence, 
apoptosis, and DNA repair219,220.The p21 (CIP1/WAF1) protein can inhibit the activity of cyclin-
CDK2, CDK1, and CDK4/6 complexes. In humans this protein is encoded by the CDKN1A gene 
located on chromosome 6 (6p21.2) and produces a polypeptide with 164 amino acids221. P21 
activity is involved in a number of human diseases such as Alzheimer222, and various types of 
cancers223, and can be regulated by different miRNAs including miR-17-92, miR-106a-363, and 
miR-106b-25 clusters224. 
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                                                                                                                                                        OBJECTIVES   
   Antibiotic-resistant bacteria that are difficult or impossible to treat are becoming increasingly 
common and are causing a global health crisis104, thus, the discovery, of new and effective 
antibiotics is urgent.  
   In this sense, nanotechnology can provide alternative approaches to tackle this problem. For 
instance, silver based nanomaterials have shown interesting antimicrobial properties. Among 
them, AgNPs are the most employed, which preparation can involve chemical, physical or 
biological transformations96. Among the latter approach, the use of bacteria to obtain AgNPs 
have several advantages compared with the other methods and yields AgNPs with high 
antibacterial properties96. Other silver derivatives with antimicrobial activity are silver 
nanoclusters (AgNCs), which have been obtained using different methods and stabilizing 
agents188,189. In the last years the use of oligonucleotides to stabilize AgNCs has attracted the 
interest of scientific community. In this case, the nanostructures obtained are fluorescent, 
which properties can be modulated by the selection of the sequence of the oligonucleotide. 
There are multiple applications of DNA-AgNCs, most of them focused in the preparation of 
sensors. However, the bactericidal properties of AgNCs stabilized by oligonucleotides (DNA-
AgNCs) have not been evaluated so far. Other methods that have shown good results in the 
treatment of resistance bacteria are those based on photodynamic therapy (PDT). In this case a 
molecule is exited by a light leading to the generation of reactive oxygen species (ROS), which 
destroy the bacteria.  To the best of our knowledge the combination of this strategy with 
AgNCs has not been assessed. 
Thus the three main objectives of the present work are: 
1. Preparation of AgNPs using bacteria obtained in Antarctica and its evaluation as 
antimicrobial. 
2. Evaluation of DNA-AgNCs as novel antimicrobials. 
3. Evaluation of PDT combined with DNA-AgNCs. 
   In addition, and related to the use of oligonucleotides for biomedical applications we plan to 
address the following objective. 
4. p21 regulation with oligonucleotides conjugated to gold nanoparticles.  
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                                                                                                                                 MATERIALS & METHODS 
 
3.1. Synthesis and antimicrobial activity of silver nanoparticles generated with Antarctic 
bacteria broths 
 
3.1.1. Bacterial isolates 
   Four bacteria were chosen from a collection of bacterial isolates obtained from ice-melting 
waters collected at the St. George Island in Antarctica. The bacteria were isolated at 4 °C using 
nutritive medium (meat extract (Merck) 3 g/l, bacto-peptone (Difco) 10 g/l, NaCl (Merck) 5 g/l). 
Bacteria were identified based on their 16S rDNA sequences. For this, a colony of each isolate 
was suspended in lysis Buffer (SDS (Merck) 0.005%, Proteinase K (Roche) 400 ng/µl) and 
treated as previously described225. This DNA containing solution was used as the template for 
the amplification by the polymerase chain reaction (PCR) of most of the 16S rDNA sequence 
using the 27F and 1492R bacteria universal primers226. The amplicons were purified by the 
polyethylenglycol-NaCl method and sequenced by Macrogen (http://www.macrogen.com). 
Sequences obtained were edited using Finch TV                                                               
(http://www. geospiza.com/Products/finchtv.shtml), and used for the phylogenetic adscription 
of the isolates by comparison with sequences in GenBank using the BLAST tool at the NCBI 
(http://blast.ncbi.nlm. nih.gov/Blast.cgi). 
 
3.1.2. Synthesis of AgNPs 
   Psychrophilic bacteria were grown in whole or NaCl-deprived nutritive medium at 4 °C or      
30 °C until the cultures achieved stationary phase. For testing the capability of broths to 
synthesize AgNPs, cells were eliminated by centrifugation at 17.530 × g at 4 °C and 
supernatants filtered through 0.22 µm pore size filters (Millipore). Supernatants were kept at   
4 °C until used in the next few days. For AgNPs synthesis, equal volumes of supernatant and      
2 mM AgNO3 (Merck) solution were mixed and kept at the required temperature under 
fluorescent household lamps or in the dark. For kinetics studies, aliquots were taken at 
different times and the UV–vis spectrum recorded. Controls experiments containing         
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AgNO3 (1mM), and medium supplemented with AgNO3 were set and treated in the same light 
and temperature conditions. 
 
3.2. Characterization of AgNPs 
 
3.2.1. UV–vis spectroscopy 
   A spectrophotometer (WPA Biowave II+) was used for spectra recording between 300 and 
700 nm, using the software provided by the company (PVC Biochrom). Measurements were 
done in conditions in which absorbance at λmax was <1.5 by using dilutions of the samples in 
distilled water when needed. 
 
3.2.2. Total Reflection X-ray Fluorescence (TXRF) 
   TXRF was used to determine AgNPs composition and concentration. AgNPs preparations 
were centrifuged to recover NPs (17.530 × g, 30 min), which were then washed twice with 
Milli-Q water before sent to the X-Ray facility of the Servicio Interdepartamental de 
Investigación (SIdI) at the Universidad Autónoma de Madrid. TXRF analysis were performed 
with a benchtop S2 PicoFox TXRF spectrometer from Bruker Nano (Germany), equipped with a 
molybdenum X-ray source working at 50 kV, 600 µA and 500 s with a XFlash SDD detector, 
effective area of 30 mm2 and an energy resolution better than 150 eV for Mn K  . 
 
3.2.3. Transmission Electron Microscopy (TEM) 
   AgNPs, samples were deposited on carbon covered copper grids and dried before visualizing 
them at the Electron Microscopy Service of the Centro de Biología Molecular Severo Ochoa 
under a JEM1010 Jeol (Japan) microscope working at 80 Kv. Photographs were taken using a 
TemCam F416 from TVIPS (Gauting, Germany), with a 4K ×  4K sensor. For size determination, 
the Image J software (http://imageJ.nih.gov/ij) was used.  
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3.2.4. X-Ray Diffraction (XRD) 
   A diffractometer X’Pert PRO theta/2theta from Panalytical, with a Ge primary 
monochromator (Johansson monochromator) and an X’Celerator detector was used for 
analysis of the crystal structure of the AgNPs deposited on glass 2 × 2 cm microscope 
coverslips. 
 
3.2.5. Dynamic Light Scattering (DLS) 
   The zeta potentials of AgNPs were measured at the Instituto Madrileno de Estudios 
Avanzados en Nanociencia (IMDEA) using a Zetasizer Nano series apparatus and Malvern 7.01 
software. 
 
3.3. Antimicrobial activity of AgNPs 
   To test antimicrobial activity, three types of bacteria were used: two Gram-negative: 
Escherichia coli (ATCC: 10536) and Klebsiella pneumoniae (ATCC: 29665), and a Gram-positive: 
Staphylococcus epidermidis ( ATCC: 12128). Bacteria were grown in nutritive medium at 37 °C 
in a shaker at 230 rpm, then a dilution in fresh medium was performed and growth checked at 
550 nm until the optical density (OD) reached 0.5. 
   For testing the antimicrobial activity of AgNPs, these were pelleted 30 min at 17530 × g, the 
supernatant removed and NPs resuspended in sterile Milli-Q water. For each AgNPs 
preparation, the UV–vis spectrum was recorded. Serial half dilutions of the AgNPs were 
performed in sterile Milli-Q water down to 1/64 and used for the tests, which were done in 
microtiter 96 wells plates, with duplicates for each concentration. Turbidity at 550 nm was 
recorded every hour in a Benchmark microplate reader (Biorad). For comparisons and IC50 
calculations a 7h time of incubation was chosen. Concentrations of AgNPs preparations were 
determined by quantitative TXRF analysis of silver and NPs concentration expressed as their 
silver content. The IC50 data were extracted by using the Prism 6 software 
(http://www.graphpad.com/scientific-software/prism/). 
   The antibacterial activity of citrate-stabilized AgNPs (SIGMA) with a 10 nm average diameter 
size was determined to compare to the activity of biological AgNPs. Those NPs were treated in 
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the same way than the previous AgNPs. They were recovered by centrifugation from the 
commercial suspension and resuspended in Milli-Q water to be added to the bacterial cultures. 
The concentration of NPs was expressed as the silver concentration measured by TXRF. 
 
3.4. DNA Silver Nanoclusters as novel nanoantibiotics 
3.4.1. Oligonucleotide Synthesis  
   The oligonucleotides were prepared using a MerMade4 DNA Synthesizer using commercial 
phosphoramidites (Link Technologies). After the automated synthesis, the solid supports were 
transferred to a screw-cap glass vial with 2 ml of ammonia solution (33 %) and incubated at 
room temperature for 16h. Then, the solutions were transferred to microcentrifuge tubes and 
evaporated to dryness using an evaporating centrifuge. 
   The samples were purified by polyacrylamide gel electrophoresis 20% and the 
oligonucleotides eluted from gel fractions using an elutrap system. The solutions were desalted 
using a NAP-10 column and concentrated in an evaporating centrifuge. 
 
3.4.2. Quantification of oligonucleotides 
   The concentration was obtained measuring the absorbance at 260 nm in a plate reader           
( BioTek-Synergy H4). The Extinction Coefficients were obtained from Integrated DNA 
Technologies (IDT, http://eu.idtdna.com/calc/analyzer). 
 
3.4.3. MALDI-TOF MS 
   Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
were used to determine the mass of oligonucleotides using 2,5-dihydroxyacetophenone      
(2,5-DHAP) as matrix at the 'Centro Nacional de Biotecnología', member of ProteoRed network 
(Table 3.1).  
 
 39 
 
3 MATERIALS & METHODS 
 
Table 3.1. Sequences employed for the preparation of AgNCs. 
 
3.5. Synthesis of AgNCs 
   To an aqueous solution of the corresponding oligonucleotide (25 µmol), six equivalents of 
AgNO3 per oligonucleotide strand were added. The final volumes were adjusted to 100 µl. The 
mixtures were incubated at room temperature for 10 min. Then, six equivalents, per strand, of 
a fresh solution of NaBH4 were added to each sample and vortexed for 1 min. The resulting 
solutions were stored in darkness at room temperature for 6h and the excess of reagents 
removed using Amicon centrifuge filters (3K). The course of the reactions was monitored by 
fluorescence (BioTek-Synergy H4). 
 
 
 
                                      
Name Sequence 
λex-λem 
(nm) 
Emitting 
Color 
Calculated mass Found 
Seq-1 
 
Seq-2 
 
Seq-3 
 
Seq-4 
 
Seq-5 
 
Seq-6 
 
Seq-7 
 
Seq-8 
 
Seq-9 
 
Trimer (Seq-3)  
5´-TTTTCCCCTTTT-3´ 
 
5´-CCCTTAATCCCC-3´ 
 
5´-CCCCCCCCCCCC-3´ 
 
5´-CCCTTTAACCCC-3´ 
 
5´-CCCCTTTTCCCC-3´ 
 
5´-GGGTTAGGGTCCCCCCACCCTTACCC -3´ 
 
5´-GGGTGGGTCCCCCCACCCACCC -3´ 
 
5´-CCTCCTTCCTCC -3´ 
 
5´-AGGTCGCCGCCC  -3´ 
 
(5´-CCCCCCCCCCCC-3´)3-Benzene 
370/475 
 
480/572 
 
540/580 
 
340/485 
 
340/495 
 
494/570 
 
512/582 
 
525/620 
 
540/629 
 
540/580 
Blue 
 
Yellow 
 
Red 
 
Blue 
 
Blue 
 
Yellow 
 
Yellow 
 
Red 
 
Red 
 
Red 
 
3528.3 
 
3501.3 
 
3408.2 
 
3501.3 
 
3468.3 
 
7844.1 
 
6618.3 
 
3468.3 
 
3607.4 
 
11206.1 
 
3518.01 
 
3493.05 
 
3407.4 
 
3499.7 
 
3466.7 
 
6218 
 
6626 
 
3466.7 
 
3605.9 
 
11200.3 
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3.5.1. TXRF 
   TXRF was used to measure silver composition and concentration in the aqueous solution of 
DNA-AgNCs (Seq-1, Seq-2 and Seq-3). TXRF analysis of the DNA-AgNCs samples (200µl) was 
performed at the X-Ray facility of the Servicio Interdepartamental de Investigacion (SIDI) at the 
Universidad Autonoma de Madrid in a benchtop S2 PicoFox TXRF spectrometer from Bruker 
nano (Germany) equipped with a molybdenum X-ray source. 
 
3.5.2. Circular Dichroism (CD) 
   Structural changes of the oligonucleotides were determined by CD using a JASCO (J-815 CD 
Spectrometer). 150µl of each sample (Seq-1, Seq-2, and Seq-3) before and after formation of 
AgNCs was employed.  
   CD spectra were determined using a Jasco J-815 CD spectrometer and 1 mm path length 
quartz cells at room temperature. The scanning speed was adjusted to 200 nm/min, and three 
accumulations were acquired. 
 
3.6. Synthesis of AgNPs 
   AgNPs were synthesized by the chemical reduction of AgNO3, using the same procedure 
employed for AgNCs but without the addition of the oligonucleotides (See 3.5). The UV-Vis 
spectra showed characteristic peak at 390 nm due to the formation of AgNPs.  
 
3.7. Antibacterial activity test 
3.7.1. Growth Curve Method 
   Escherichia coli DH5 alpha (ATCC:668369, Gram-negative) and Staphylococcus epidermidis 
(ATCC:6538p, Gram-positive) bacteria were chosen as a bacterial model to study the 
antibacterial properties of DNA-AgNCs. 
   The susceptibility of E.coli and S.epidermidis were first determined by growth curve method. 
Bacteria were cultured in Luria-Bertani (LB) medium to saturation. Bacteria culture was diluted 
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and grown for two hours until mid exponential phase (OD=0.5). Then, the bacteria culture was 
diluted to an OD (650nm = 0.1) in LB, as the starting point of the growth curve, and incubated 
at 37 °C for 14 h under shaking. DNA-AgNCs concentration was adjusted to 0.750 µM, 1.5 µM, 
2.25 µM, 3 µM, 4 µM and 5 µM (based on the oligonucleotides absorbance) in a final volume of 
200µl. The corresponding oligonucleotides were used at the same concentration as controls, as 
well as, AgNO3 and AgNPs. Bacterial growth was determined by measuring the optical density 
(OD) at 650 nm every 1 h. 
 
3.7.2. Agar Disk Diffusion Test 
   Kirby-Bauer disk diffusion susceptibility test was performed to determine the antibacterial 
activity of complexes formed with Seq-1, Seq-2 and Seq-3. For this purpose, E.coli bacteria were 
cultured in LB agar medium. DNA-AgNCs (5µmol) were placed on sterile paper discs, which 
were transferred to the agar plate and incubated at 37 °C for 24h. The presence or absence of 
inhibition zone is used as indicator of the sensitivity or resistance of the bacteria. 
 
3.8. Synthesis of Trimers-DNA AgNCs 
1,3,5-tris(azidomethyl) benzene  
 
 
   To a suspension of LiAlH4 (247 mg, 6.5 mmol) in THF (5 ml) under N2, was added slowly a 
solution of trimethyl benzene-1,3,5-tricarboxylate (500 mg, 1.97 mmol) in THF (5ml) and stirred 
for 16h at room temperature. The reaction mixture was hydrolyzed with MeOH at 0 °C and 
then with a saturated solution of sodium tartrate during 2 h. The mixture was washed with 
AcOEt and the aqueous phase acidified with HCl until neutral pH. Then, it was extracted with 
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AcOEt and after solvent evaporation the 1,3,5-tribenzyl alcohol was obtained and used without 
further purification as a colorless oil with 56% yield. 
   To a suspension of 1,3,5-tribenzyl alcohol (205 mg, 1.22 mmol) in (Et2O 10 ml), PBr3             
(285 µl,3 mmol) was added and stirred for 16h. The mixture was hydrolyzed with a saturated 
solution of NaHCO3 and extracted with AcOEt. After solvent evaporation, the white solid 
obtained was dissolved in DMF (5 ml) and NaN3 (253 mg, 3.9 mmol) added and heated at 80 °C 
during 3 h. The mixture was washed with water, brine and extracted with AcOEt. After flash 
chromatography (eluent Hexane/AcOEt 8:1) 1,3,5-tris(azidomethyl) benzene was obtained as a 
colorless oil in 90% yield; 1H NMR (300 MHz, CDCl3) δ 7.26 (s, 3H), 4.40 (s, 6H). 
 
3.9. Synthesis of modified solid support A (CPG-A)146 
 
 
 
Figure3.2. Summary of CPG preparation. 
 
 
 
 
 
 43 
 
3 MATERIALS & METHODS 
N-((2R,3R)-1,3-dihydroxybutan-2-yl)pent-4-ynamide  
 
 
 
 
   To a stirred mixture of 4-pentynoic acid (294 mg, 3.6 mmol), N-hydroxybenzotriazole         
(444 mg, 3.1 mmol) and N,N′-Diisopropylcarbodiimide (510 µL, 3.1 mmol) in DMF (7.2 ml) 
under N2, L-threoninol (315 mg, 3mmol) was added at room temperature. After 16 h the 
reaction mixture was quenched with MeOH and the solvent evaporated in vacuum. After 
solvent evaporation and flash chromatography (eluent CH2Cl2/Hexane/MeOH 10:1:1) the 
desired compound was obtained as a colorless oil, in 94% yield; 1H NMR (300 MHz, CDCl3) δ 
6.47 (s, 1H), 4.18 (d, J = 5.9 Hz, 1H), 3.82 (bs, 3H), 2.66 – 2.35 (m, 5H), 1.21 (d, J = 6.1 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 172.4, 82.8, 69.6, 67.7, 63.9, 55.1, 35.4, 20.2, 15.0; MS (ESI): m/z 
(%) 136 (27), 168 (M+-OH, 39), 186 (M++H, 25), 208 (M++Na, 100); HRMS (ESI) calculated for 
C9H15NO3 (M
++H) 186.1124, found 186.1141. 
N-((2R,3R)-1-(bis(4-methoxyphenyl)(phenyl)methoxy)-3-hydroxybutan-2-yl)pent-4-ynamide  
 
 
   To a solution of the alkyne obtained previously (525 mg, 2.83 mmol) in pyridine (14 ml) at      
0 °C, DIPEA (730 µl, 4.2 mmol), 4,4’-dimethoxytrithylchloride (1.15 g, 3.4 mmol) and DMAP 
(catalytic amount) were added. The mixture was stirred and allowed to reach room 
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temperature slowly. After 16 h, the solvent was evaporated and the residue purified by flash 
chromatography (eluent Hex/AcOEt 1:5 using silica gel deactivated with Et3N) to obtain the 
desired DMT protected derivative in 65% yield as a yellow solid; 1H NMR (300 MHz, CDCl3) δ 
7.42 (d, J = 7.2 Hz, 2H), 7.32 (d, J = 8.8 Hz, 4H), 7.38 – 7.22 (m, 3H), 6.88 (d, J = 8.8 Hz, 4H), 6.31 
(d, J = 8.6 Hz, 1H), 4.22 – 4.09 (m, 1H), 3.99 (dd, J = 8.3, 2.4 Hz, 1H), 3.83 (s, 6H), 3.41 (ddd,         
J = 13.0, 9.6, 3.8 Hz, 2H), 2.63 – 2.44 (m, 4H), 2.02 (t, J = 2.4 Hz, 1H), 1.18 (d, J = 6.3 Hz, 3H); 13 C 
NMR (75 MHz, CDCl3) δ 171.3, 158.6, 144.3, 135.5, 135.3, 129.9, 129.9, 128.0, 127.9, 127.0, 
113.3, 86.8, 82.9, 69.5, 68.6, 65.3, 55.2, 53.4, 35.5, 19.8, 15.0; MS (ESI): m/z (%) 303 (100), 510 
(M++Na, 23); HRMS (ESI) calculated for C30H33NO5 (M
++Na) 510.2250, found 510.2249. 
 
3.9.1. Solid Support A preparation 
 
 
   To a solution of DMT derivative obtained before (27 mg, 0.055mmol) in CH2Cl2 (0.4 ml), 
succinic anhydride (7.2 mg, 0.072 mmol), DIPEA (14 µl, 0.077 mmol) and DMAP (catalytic 
amount) were added under N2 at room temperature. The mixture was stirred during 16 h, 
washed with water and dried with MgSO4. After solvent evaporation, the residue obtained was 
dissolved in CH3CN (1.2 ml) and DMAP was added. This solution was added to an eppendorf 
containing 2,2′-Dithiobis(5-nitropyridine) (25 mg, 0.08 mmol) and vortexed. This solution was 
added to a second eppendorf containing PPh3 (21 mg, 0.08 mmol) and vortexed until complete 
dissolution. This mixture was added to 200 mg of Aminopropyl-CPG (500 Å) and stirred during 
2h. The solvent was removed and the CPG washed with MeOH and CH3CN. Once the CPG was 
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dry, 2 ml of a 1:1 mixture of capping reagents used on oligonucleotides synthesis [CAP MIX A: 
Acetic anhydride (400 µl)/ Py (600 µl)/ THF ( 500 µl); CAP MIX B: 1-Methylimidazol (400 µl)/ 
THF (1ml)] was added and stirred. After 25 min, the modified CPG was washed with MeOH, 
CH3CN, and dried. 
   The CPG loading was calculated using the trityl quantification method. 10 mg  of the modified 
CPG was treated with 5 ml of a detritylation solution (3 ml of perchloric acid and 2 ml of EtOH) 
and stirred during 30 min. Then, 100 µl of the mixture was diluted to 2.5 ml, and the 
absorbance was measured at 498 nm to quantify the trityl cation. Functionalization (F) was 
determined by Lambert-Beer law. The extinction coefficient (ε) at this wavelength is 70000 mol 
-1 dm3 cm-1. The loading obtained was 73.6 µM/gr. 
 
3.9.2. Seq-3-alkyne modified click reaction 
   Seq-3 was synthesized with alkyne moiety at the 3’-end the modified CPG and then used in 
the preparation of Trimers through click reaction.  
   To an aqueous solution of the azide derivative (0.075 µmol), Seq-3-Alkyne (0.30 µmol,             
4 equiv), NaCl (0.13M), CuI (1.78 mg, 9.35 µmol) and a solution of TBTA (tris[1-benzyl-1H-1,2,3-
triazol 4yl)methyl] amine) (7.14 mg, 13.46 µmol) in DMF (357 µl) were added. The reaction was 
maintained at 55 °C for 16 hours. The product was purified by polyacrylamide gel 
electrophoresis 20% and eluted from gel fractions using an elutrap system. The solution was 
desalted using a NAP-10 column and concentrated in an evaporating centrifuge.  
 
 
 
 
 
 
 
 
       46 
 
3 MATERIALS & METHODS 
3.10. ROS Detection 
   To demonstrate the production of ROS in the presence of the different silver species used in 
this work, we used 2´,7´-dichlorodihydrofluorescin diacetate (DCFH-DA) as probe. In the 
presence of ROS, the acetyl residues are removed yielding the corresponding intermediate 
(DCFH), which is oxidized to the fluorescent 2’,7’-dichlorofluorescin (DCF)227. 
   Briefly, E. coli and S. epidermidis cells (OD 650= 0.1) were treated with 6 µl of a solution 
(0.750 µM) of the corresponding silver derivative, and incubated during 15h in a microplate 
reader, where the OD was recorded at intervals of 1h. At the end of the incubation time, cells 
were spun down at 9,300 х g, 4 °C for 5 min, washed thrice with water and resuspended in 
water. Then, 10 µl DCFH-DA (5 µM) was added and the final volumes adjusted to 200 µl. The 
cells were incubated during 2h at room temperature, with mild shaking (80 rpm) and in the 
dark. The fluorescence intensity was recorded (λex/em= 488- 525 nm) after 2h. The ROS 
concentration can be directly related to the fluorescence intensity of the DCF dye. The ROS 
concentration was normalized by the cell density.  
 
3.11. Modified oligonucleotides in photodynamic therapy for bacteria growth control 
3.11.1. Synthesis of oligonucleotides bearing a photosensitizer 
   Different, oligonucleotides were prepared and purified containing hexachlorofluorecein (HEX) 
at the 5’end using the procedures described before for other oligonucleotides (Table 3.2). 
 
Table 3.2. MALDI-TOF of the PS1, PS2, and PS3. 
Name Sequence               Calculated mass Found 
PS1 
 
PS2 
 
PS3 
5´-HEX- CCCTTAATCCCC-3´ 
 
5´-HEX- CCCCCCCCCCCC-3´ 
 
5´-HEX- GGGTGGGTCCCCCCACCCACCC -3´ 
 
4245.43 
 
4152.33 
 
7362.43 
4245.10 
 
4152.08 
 
7360.21 
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3.11.2. Synthesis of AgNCs 
   AgNCs were obtained as described before using the oligonucleotides modified with HEX. 
 
3.11.3. Photodynamic therapy using oligonucleotides bearing HEX 
   The antibacterial activity test was carried out using two Gram-negative bacteria E.coli DH5 
alpha (ATCC:668369) and Pseudomonas aeruginosa (ATCC:10145) and one Gram-positive 
bacteria Staphylococcus aureus (ATCC:25922). The susceptibility of E. coli, P. aeruginosa and 
S.aureus were determined by the growth curve method. Particularly, bacteria were cultured in 
LB medium to saturation, diluted and grown for two hours until mid exponential phase 
(OD=0.5). Then, the bacteria were diluted to an OD of 0.1 in LB, (the starting point of the 
growth curve), photoirradiated under the light system (intensity: 2.45 mwcm-2 at 525 nm) for 2 
hours and incubated at 37 °C for additional 24 h under mild shaking. HEX-DNA and HEX-DNA-
AgNCs concentration was adjusted to 0.750 µM, 1.5 µM and 3 µM in a final volume of 200 µl. 
An oligonucleotide without HEX (Seq8 ), AgNO3 and AgNPs were used as controls. The 
production of ROS was evaluated as described previously suing the DCFHDA probe (See 3.11). 
 
3.12. p21 regulation with oligonucleotides conjugated to gold nanoparticles 
 
3.12.1. Synthesis of citrate-capped AuNPs 
   To a boiling solution of HAuCl4 (100 ml, 1 mM) in water, trisodium citrate (10 ml, 38.8 mM) 
was added and stirred for 15 min. The mixture was allowed to reach room temperature and 
filtered. Using its corresponding Extinction Coefficient (2.7 × 108M-1cm-1) and the Lambert-
Beer’s law the concentration was determined (13 nM). 
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Synthesis of modified solid support B for the release of oligonucleotides (CPG-B) 
Synthesis of N-((2R,3R)-1,3-dihydroxybutan-2-yl)-3-mercaptopropanamide(A) . 
 
   To a stirred mixture of 3-mercaptopropionic acid (100 mg, 0.94 mmol), N-hydroxybenzotriazole 
(135 mg, 1 mmol) and  N,N´-Dicyclohexylcarbodiimide (206 mg, 1 mmol) in DMF (3 ml) under N2, 
L-threoninol (100 mg, 0.94 mmol) was added at room temperature. After 16 h the reaction 
mixture was quenched with MeOH and the solvent evaporated in vacuum. To the residue 30 ml of 
CH2Cl2 was added, and the solid filtered off. After solvent evaporation and flash chromatography 
(eluent CH2Cl2/MeOH 15:1) compound A was obtained as a colorless oil, in 65% yield; 
1H NMR (300 
MHz, CDCl3) δ 6.55 (s, 1H), 4.17 (qd, J = 6.1, 2.0 Hz, 1H), 4.03 – 3.64 (m, 3H), 3.02 – 2.67 (m, 2H), 
2.57 (t, J = 6.6 Hz, 2H), 1.63 (t, J = 8.3 Hz, 1H), 1.20 (d, J = 6.4 Hz, 3H); 13C NMR (75MHz, CDCl3) 
δ172.2, 67.7, 63.9, 55.1, 40.3, 29.6, 20.5; MS (ESI):m/z (%) 176 (M+-OH, 11), 194 (M++1, 10), 216 
(M++Na, 100); HRMS (ESI) calcd for C7H15NO3S (M
++1) 216.0660, found 216.0664. 
Synthesis of 2-(Pyridyldithio)-ethylaminehydrochloride(PDA*HCl). 
 
   PDA*HCl was synthesized as reported (G.T. Zugates, D. G. Anderson, S. R. Little, I. E. B. Lawhorn, 
R Langer, J. Am. Chem. Soc. 2006, 128, 12726-12734 )with some modifications. To a stirred 
solution of aldrithiol (213 mg, 0.96 mmol) in MeOH (1.1 ml), 2-mercaptoethylamine hydrochloride 
(109 mg, 0.96 mmol) was added. After stirring 1h, the solvent was evaporated and the residue 
washed with cold AcOEt three times. PDA*HCl was obtained as a white solid in 51% yield: 1H NMR 
(300 MHz, d6-CD3OD)δ8.57 (d, J = 5.0 Hz, 1H), 7.83 (t, J = 7.7 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.35 
(dd, J = 7.5, 5.0 Hz, 1H), 3.18 (t, J = 6.1 Hz, 2H), 3.07 (t, J= 6.8 Hz, 2H); MS (ESI):m/z (%) 107 (100), 
153 (79), 187 (M+-Cl, 12); HRMS (ESI) calcdfor C7H11NS2(M
++1) 187.0366, found187.0391. 
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Synthesis of (R)-5-(1,2-dithiolan-3-yl)-N-(2-(pyridin-2-yldisulfanyl)ethyl)pentanamide (B). 
 
   To a stirred mixture of (R)-(+)-α-Lipoic acid (134mg, 0.65 mmol),  N-hydroxybenzotriazole         
(96 mg, 0.71 mmol) and  N,N´-Dicyclohexylcarbodiimide (147, 0.71 mmol) in DMF (1.7 ml) under 
N2, PDA*HCl  (145 mg, 0.65 mmol) and DIPEA (147 µl, 0.71 mmol) were added at room 
temperature. After 16 h the reaction mixture was quenched with MeOH and the solvent 
evaporated in vacuum. To the residue 30 ml of CH2Cl2 was added, and the solid filtered off. After 
solvent evaporation and flash chromatography (eluent CH2Cl2/AcOEt 1:1) compound B was 
obtained as a colorless oil, in 14% yield;1H NMR (300 MHz, CDCl3) δ 8.48 (dd, J = 3.7, 1.1 Hz, 1H), 
7.70 – 7.56 (m, 1H),7.51 (d, J = 8.0 Hz, 1H),7.23 – 7.08 (m, 2H),3.64 – 3.46 (m, 3H),3.22 – 3.02 (m, 
2H),2.96 – 2.85 (m, 2H),2.43 (dq, J = 12.5, 6.4 Hz, 1H),2.21 (t, J = 7.4 Hz, 2H),1.97 – 1.80 (m, 
1H),1.78 – 1.57 (m, 5H),1.54 – 1.38 (m, 2H);13C NMR (75MHz, CDCl3)δ172.9, 159.2, 149.7, 137.1, 
121.4, 121.2, 95.7, 77.5, 77.1, 76.7, 56.4, 40.3, 39.0, 38.5, 37.3, 36.6, 34.7, 29.0, 25.4; MS (ESI):m/z 
(%) 225 (52), 264 (10), 375 (M++1, 100); HRMS (ESI) calcdfor C15H23N2S4 (M
++1) 375.0675, 
found375.0687. 
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 Synthesis of N-(2-((3-((2R,3R)-1,3-dihydroxybutan-2-ylamino)-3-oxopropyl)disulfanyl)ethyl)-5-
((R)-1,2-dithiolan-3-yl)pentanamide (C) 
 
   To a solution of disulfide B (45 mg, 0.12 mmol) in MeOH (1 ml) under N2, a solution of compound 
A (23 mg, 0.12 mmol) in MeOH (1 ml) was added and stirred for 2 h. The solvent was evaporated 
and the residue purified by flash chromatography (CH2Cl2/MeOH 20:1) to obtain compound C as 
colorless oil in 88% yield; 1H NMR (300 MHz, CDCl3)δ6.88 (d, J = 8.3 Hz, 1H), 6.61 (t, J = 5.6 Hz, 1H), 
4.23 – 4.03 (m, 1H), 3.91-3.74 (m, 5H), 3.62 – 3.47 (m, 3H), 3.02 (t, J = 6.8 Hz, 2H), 2.83 (t, J = 6.5 
Hz, 2H), 2.68 (t, J = 6.7 Hz, 2H), 2.45 (dq, J = 12.4, 6.4 Hz, 1H), 2.22 (t, J = 7.4 Hz, 2H), 1.90 (dq,         
J = 13.7, 6.9 Hz, 1H), 1.78 – 1.55 (m, 5H), 1.45 (m, 3H), 1.19 (d, J = 6.4 Hz, 3H).13C NMR (75 MHz, 
CDCl3) δ 173.9, 171.9, 68.6, 64.6, 56.4, 55.1, 40.2, 38.6, 38.5, 38.3, 36.5, 36.3, 34.9, 34.5, 28.8, 
25.3, 20.4; MS (ESI):m/z (%) 301 (13), 457 (M++1, 14),479 (M++Na, 100); HRMS (ESI) calcd for 
C17H33N2O4S4 (M
++1) 457.1334, found 457.1317; HRMS (ESI) calcd for C17H32N2O4NaS4 (M
+) 
479.1166, found 479.1137. 
 
Synthesis of N-(2-((3-((2R,3R)-1-(bis(4-methoxyphenyl)(phenyl)methoxy)-3-hydroxybutan-2-
ylamino)-3-oxopropyl)disulfanyl)ethyl)-5-((R)-1,2-dithiolan-3-yl)pentanamide (D). 
 
   To a solution of compound C (74 mg, 0.16 mmol) in pyridine (0.8 ml) at 0 ºC, DIPEA (43 µl,       
0.24 mmol) and 4,4’-dimethoxytrithylchloride ( 64 mg, 0.19 mmol) were added. The mixture was 
stirred and allowed to reach room temperature slowly. After 16 h, the solvent was evaporated and 
the residue purified by flash chromatography (eluent Hex/AcOEt 1:9 using silica gel deactivated 
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with Et3N) to obtain compound D in 35% yield as a yellow solid; 
1H NMR (300 MHz, CDCl3) δ7.39 – 
7.27 (m, 2H), 7.27 – 7.11 (m, 7H), 6.76 (d, J = 8.8 Hz, 4H), 6.41 – 6.21 (m, 2H), 4.13 – 3.96 (m, 2H), 
3.95 – 3.83 (m, 1H), 3.71 (s, 6H), 3.42-3.51 (m, 3H), 3.28 (ddd, J = 36.7, 9.6, 4.1 Hz, 2H), 3.13 – 2.97 
(m, 2H), 2.92 (t, J = 6.8 Hz, 2H), 2.73 (t, J = 6.2 Hz, 2H), 2.57 (td, J = 6.9, 2.7 Hz, 2H), 2.45 – 2.26 (m, 
1H), 2.10 (t, J = 7.4 Hz, 2H), 1.80 (dq, J = 13.5, 6.9 Hz, 1H), 1.57 (qd, J = 13.2, 11.1, 6.8 Hz, 4H), 1.46 
– 1.26 (m, 2H), 1.07 (d, J = 6.4 Hz, 3H); MS (ESI): m/z (%) 303 (100), 781 (M++Na, 15); HRMS (ESI) 
calcd for C38H50N2O6S4 (M
++Na) 781.2455, found 781.2443. 
 
Synthesis of Solid Support B (CPG-B) 
 
   To a solution of compound D (40 mg, 0.052 mmol) in CH2Cl2(0.4 ml), succinic anhydride (6.8 mg, 
0.068 mmol), DIPEA (13 µl, 0.072 mmol) and DMAP (catalytic amount) were added under N2 at 
room temperature. The mixture was stirred during 16 h, washed with water and dried with 
MgSO4. After solvent evaporation, the residue obtained was dissolved in DMF (1.2 ml), and HBOt 
(7 mg, 0.052 mmol) and DCC (10 mg, 0.052 mmol) were added. This mixture was added to 400 mg 
of CPG (500 Å) and stirred during 2h. The solvent was removed and the CPG washed with CH2Cl2 
gently. Once the CPG was dry, 2 ml of a 1:1 mixture of capping reagents used on oligonucleotides 
synthesis [CAP MIX A: Acetic anhydride (400 µl)/ Py (600 µl)/ THF ( 500 µl); CAP MIX B: 1-
Methylimidazol (400 µl)/ THF (1 ml)] was added and stirred. After 25 min, the modified CPG was 
washed with MeOH, CH3CN, and dried. 
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3.12.2. Synthesis of p21 Antisense and Gampers 
   Two Antisense oligonucleotides (Antisense 1 and 2) with and without PolyT (T5) as spacer 
were synthesized using 2´-O-Me (OMe) RNA Phosphoramidites (Link) using the solid support 
described above at the 3’-end. The antisense were designed to target the p21 gene at the 
regions 141-160 nt (antisense 1) and 521-540 nt (antisense 2) (Obtained from GenBank at the 
NCBI: Mus musculus cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, 
mRNA). In the case of Gapmers a mixture of OMe-RNA (in bold) and DNA phosphoramidides 
were employed (Table 3.3).   
 
Table 3.3. Sequences and MALDI-TOF of the Antisense and Gapmer. All sequences contain a dithiolane group at the 
3’-end.  
Name Sequence           Calculated mass Found 
Antisense 1 
 
Antisense 2 
 
Gapmer 
 
5´- AGA CAA CGG CAC ACU UUG C-TTTTT-3  ´
 
5´-AUAGAAAUCUGUCAGGCUG-TTTTT-3´ 
 
5´-GAUAGAAATCTGTCAGGCUG-3´ 
7778.7 
 
7820.7 
 
6671 
 
7653.8 
 
8130.9 
 
6575.01 
 
    
 
3.12.3. Synthesis of siRNA 
   In this case the siRNA against p21 was prepared using the sequence of the antisense 2. 
Commercial RNA phosphoramidites were employed, at uracil sites , 2’-OMe-Uracil derivatives 
were employed.  The modified CPG bearing the dithiolane moiety was employed. After solid-
phase synthesis, the solid support was transferred to a screw-cap glass vial with 2 ml of 
ammonia and 500 µl of Ethanol. The mixture was incubated at room temperature for 16 h and 
then evaporated to dryness using an evaporating centrifuge. Then, tetrabutyl ammonium 
fluoride (0.333 µl) was added and the mixture incubated at room temperature for 24 h. After 
that, 0.333 µl of triethylammonium acetate (TEAA, 1 M) in water and 0.333 µl of RNase-free 
water were added to quench the reaction. Then, the samples were desalted using NAP-10 
columns and concentrated in an evaporating centrifuge. The oligonucleotides were purified by 
polyacrylamide gel electrophoresis 20% and eluted from gel fractions using an elutrap system.    
The solutions were desalted using a NAP-10 column, concentrated in an evaporating centrifuge 
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and quantified. The desired double stranded RNA structures, were obtained by an annealing 
process where the oligonucleotides at equimolar concentrations in an annealing buffer (10 µM 
Tris, 1 µM EDTA, 50 µM NaCl ) were, heated at 90 °C for 3 min and cooled down slowly to room 
temperature. The siRNA duplexes were employed in the functionalization of AuNPs as 
described in section 3.12.2 (Table 3.4). 
 
Table 3.4. MALDI-TOF of the Passenger and Guide strands. U are modified with 2’-OMe groups. 
 
Name Sequence           Calculated mass Found 
Passenger 
 
Guide 
 
5´- CAG CCU GAC AGA UUU CUA U-TTTTT-3´ 
 
5´- AUA GAA AUC UGU CAG GCU G-3´ 
7717.6 
 
6908.1 
 
7742.2 
 
6655.9 
 
    
 
3.12.4. Modified AuNPs 
   To 1 ml of the AuNPs solution the corresponding oligonucleotides was added (1 nM) and 
incubated at the room temperature by middle shake to overnight. After 2 h of the addition 
NaCl was added to reach a final concentration of 0.3 M to improve the functionalization of the 
AuNPs. At the end of the incubation time the oligonucleotides were spun down at 16,100 х g,  
4 °C for 30 min, washed thrice and resuspended in RNase-free water and immediately were 
sent to CNB (Centro Nacional de Biotecnologia, Immunology & Oncology unit, Lab 412) for its 
evaluation (See 3.13). 
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3.13. p21 T-cell Transfection 
3.13.1. Mice 
   Control C57BL/6 mice were obtained from Harlan Interfauna Ibérica (San Felíu de Codines, 
España). C57BL/6-p21-/-mice (p21-/-) were generated by crossing p21-/-129/Sv mice 
(laboratory of Dr. Gregory Hannon, Cold Spring Harbor Laboratory, NY, USA) with C57BL/6 mice 
over eight generations. Background analysis via microsatellite markers confirmed >99% 
identity with the B6 background 56. All mouse experiments were performed in accordance 
with European Union and national regulations, and were approved by the CNB Bioethics 
Committee. 
 
3.13.2. Cell culture 
   Mouse CD4+ spleen T-cells were purified by Negative Isolation Kit (Dynal Biotech), 85% pure 
CD4+ T-cells were obtained. Purified naive T-cells (106/ml) were stimulated in vitro with 
concanavalin A (ConA; 3 mg/ml, Sigma) in medium containing 20 ng/ml human recombinant 
interleukin-2 (rIL-2, PeproTech). After 24h, cells were washed and cultured in medium with    
20 ng/ml IL-2 (5 days).  
 
3.13.3. Cell culture medium 
   Purified CD4+ T-cells were cultured in RPMI-1640 medium supplemented with 10% FCS (fetal 
calf serum, Harlan Bioproducts, SeraLab), 2 mM L-glutamine, 100 U/ml penicillin, 100  mg/ml 
streptomycin, 1 mM sodium pyruvate, 10 mM HEPES pH 7.4, 0.1 mM nonessential amino acids 
and 50 mM β-mercaptoethanol (all from Gibco Life Technologies). 
 
3.13.4. Treatment with Modified AuNPs  
   The incubation with AuNPs was carried out at the end of 5-days IL-2 expansion. T-cells were 
transfected also with siRNA against p21 using a conventional method (Amaxa-Lonza Mouse     
T-cell Nucleofector kit, VPA-1006) as a control. A nonsense sequence (poly T) was used as 
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control. Five million cells were transfected with 100 µl (different concentration from 100-200 
nm) of siRNA conjugated to AuNPs in complete medium without serum and antibiotics. 4-24 
hours after transfection, the cells were stimulated again with Con-A in presence of a caspase 
inhibitor zVAD (25 μM) in complete medium at different time points. 
   In the case of conventional method, the procedure was done according to the instruction 
manual. Briefly, the cells were centrifuged and resuspended in the 4D NucleofectorTM solution 
and siRNA added to cells. This mixture was added to the nucleocuvetteTM Vessels and 
electroporated. Pre-warmed fully supplemented Mouse T-cell NucleofectorTM medium was 
added and incubated for 4 hours. Then restimulated again with ConA and zVAD at different 
times (Fig 3.3).  
 
 
Figure3.3. T cell transfection by oligonucleotides (AuNPs and Electroporation methods). 
 
3.13.5. Western blot  
   Protein lysates of cultured cells (5 x 106 cells/sample) were obtained by lysis of CD4+ T-cells 
for 20 min on ice using a 0.2% NP-40 lysis buffer (10 mM Tris HCl pH 7.5, 150 mM NaCl, 0.2% 
NP40) supplemented with Phosphatase Inhibitor Cocktail (PhosStop) and Complete Protease 
Inhibitor Cocktail (both from Roche). After quantification of protein concentration by Bradford 
assay (Bio-Rad), equal protein amounts (5-15 μg) were separated on 12% acrylamide gels and 
transferred to a nitrocellulose membrane (Bio Rad). Membranes were blocked in 5% low fat 
milk (1x TBS + 0.05% Tween 20) and incubated with primary antibody dilutions as 
recommended by the manufacturer. Primary antibodies were purchased from Cell Signalling 
Con A
1 d 5 d
3 d+2 d
Con A+ zVAD
Transfection
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(anti-pERK, -ERK, -AKT, -pPKC), Santa Cruz Biotechnology (anti-p21, -CARMA1) or Sigma (anti-
β-actin). After incubation with appropriate peroxidase-conjugated secondary antibodies         
(all from Dako), proteins of interest were detected by chemiluminescence (ECL, Perkin Elmer) 
on  X-ray film (Kodak Minolta). 
 
3.13.6. Flow cytometry (Fluorescence-Activated Cell Sorting, FACS) 
   Transfection efficiency was evaluated by flow cytometry (CYTOMICS FC500, Beckman 
Coulter) at 24 h and 48 h after transfection 500 µl of each sample (modified AuNPs and siRNA 
using), poly T conjugated FAM (λex/em= 494-525 nm) modified AuNPs, employed as fluorescein 
dye which directly applied to the cytometry and transfection was measured in FL1 (525 nm).  
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4 RESULTS 
                                                                                                                                                                    RESULTS  
 
4.1. Synthesis and antimicrobial activity of silver nanoparticles generated with Antarctic bacteria 
broths 
 
4.1.1. Synthesis of AgNPs 
   Silver nanomaterials have been produced using different bacteria, however, the reports where 
extremophiles66 and particularly psychrophilic bacteria68,69 are scarce. 
   In the present study, four psychrophilic bacteria isolated from Antarctic ice-melting waters have 
been identified by molecular analysis and their broths employed in the synthesis of AgNPs.  
   Their phylogenetic adscription was confirmed from a unique colony on nutritive solid medium 
through PCR amplification of the 16S rDNA genes, and sequencing using universal primers226.  
The isolated bacteria are strains belonging to the following species: 
Psychrobacter sp228. A Gram-negative, osmotolerant, oxidase-positive, and aerobic bacteria, 
considered rare opportunistic human pathogen. 
Aeromonas salmonicida229. A Gram-negative, facultative anaerobic, non-motile bacterium, which is a 
fish pathogen. 
Pseudomonas veronii230. A Gram-negative, rod-shaped, motile bacterium, which have industrial 
applications, such as bioremediation of contaminated soils from aromatic organic compounds. 
Yersinia kristensenii231. A Gram-negative bacteria that is potentially infectious to mice. 
   To the best of our knowledge, the production of AgNPs mediated by these types of bacteria have 
not been evaluated. In this case, broths of cultures of the different bacteria were incubated with 
AgNO3 to yield AgNPs. Since the bacteria employed are psychrophilic (grow in cold waters) we 
decided to evaluate the effect of the temperature during the production of the broths and also 
during the reaction with AgNO3. Particularly, two different temperatures were evaluated, 4 °C and  
30 °C.  
   The effect of the light was also assessed, since it has been shown that it is required in the 
biosynthesis of AgNPs232,233 particularly the use of blue light234, although in some cases AgNPs can be 
obtained without light235. 
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   In addition, the effect of NaCl in the reaction mixture was also studied. Different reports have 
shown that the presence of NaCl during the biosynthesis of AgNPs might induce their aggregation or 
decrease their yield236,237, probably be due to the formation of the insoluble AgCl in the reaction 
mixture. However, N. Mokhtari et al, have reported that AgCl itself could be employed in the 
preparation of AgNPs using supernatants from Klebsiella pneumonia 238. In addition, psychrophilic 
bacteria can stand salty water better than other bacteria. For these reason we decided to check the 
effect of NaCl in the production of AgNPs 238, 239.  
   Bacteria were grown in nutritive medium with and without NaCl at 4 °C or 30 °C. The corresponding 
supernatants were mixed with AgNO3 (1 mM) and kept in the light or in the dark. The generation of 
AgNPs was followed by UV-vis spectroscopy, since they present a characteristic band around         
400-450 nm due to the surface plasmon resonance (Fig 4.1). In our case, the production of AgNPs 
was only observed when the process was carried out under the light.  
 
 
Figure 4.1. UV-spectra of reaction mixtures incubated in the dark during 5 days. A). at 30 °C and B). at 4 °C., and in the light 
during 5 days. C). at 30 °C and D). at 4 °C.  
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   The UV-Vis spectra of the samples revealed that the production of AgNPs using broth from cultures 
containing NaCl (5 g/l, 85.5 mM) was lower than those carried out without NaCl at both 
temperatures (Fig 4.2). The low temperature (4 °C) also reduced the formation of AgNPs                  
(Fig 4.2C and 4.2D), and when the addition of NaCl and low temperature where combined, the 
generation of AgNPs was completely suppressed (Fig. 4.2D).  
 
 
 
Figure 4.2. Comparison of UV-vis spectra of AgNPs produced with broths A). without NaCl ,B). with NaCl at 30°C and C). whitout 
NaCl, D).with NaCl at 4°C. 
 
   The evolution of the AgNPs was followed by UV-Vis spectrophotometry during many days. Broths 
from Y. kristensenii produced AgNPs more efficiently at both temperatures (Fig 4.3 and 4.4), reaching 
the maximum after 19 days at 30 °C and after 298 days at 4 °C. On the other hand, broths from         
A. salmonicida at 4 °C, were the less active. These results correlate well with the yields obtained at 
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4 RESULTS 
day 9 from aliquots of each experiment (Table 4.1). Yields were obtained after 9 days by removing 
AgNPs from the suspension by centrifugation, and measuring silver concentration in the 
supernatants.  
   We observed that using broths of Psychrobacter sp. at 4 °C and Y. kristensenii at 30 °C the shape of 
the spectra showed a bimodal distribution with peaks at 394 and 403 in the first case and 461 and 
464 nm in the later one. However only a single peak was detected after longer incubation times.  
 
 
 
Figure 4.3 . UV-Vis spectra due to the generation of AgNPs along several days at 30 °C using broths from cultures of 
psychrophilic bacteria. A). Psychrobacter sp, B). A. salmonicida, C). P.veronii, D). Y.kristensenii. 
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Figure 4.4  UV-Vis spectra due to the generation of AgNPs along several days at 4°C using broths from cultures of 
psychrophilic bacteria. A). Psychrobacter sp, B). A. salmonicida, C). P.veronii, D). Y.kristensenii. 
 
4.1.2. Characterization of AgNPs 
   The shapes and sizes of AgNPs obtained at 30 °C (Fig. 4.5) and 4 °C (Fig 4.6) were studied by  TEM. 
The shape of all the AgNPs was nearly spherical. The average size of AgNPs produced by the different 
bacteria was around 6 nm, with the exception of the AgNPs obtained with broths from                        
A. salmonicida at 30 °C, which were noticeably larger (average size 11.1 nm) (Figure 4.6B). 
   Size distributions for the different AgNPs are shown as histograms in (Fig 4.7 and 4.8), where the 
averages sizes and PDIs obtained from the different broths and temperatures are summarized in 
Table 4.1. PDIs were calculated using the formula: PDI= (σ/γ)241, were σ is the standard deviation of 
the measured diameter sizes of the NPs, and γ their mean242. 
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Table 4.1. Yields, sizes and PDI obtained at different temperatures. 
 
    
   PDI of 0.0 corresponds to monodisperse AgNPs, up to 0.1 AgNPs are considered very close 
monodisperse, from 0.1 to 0.4 AgNPs are moderate polydisperse, and values >0.4 indicate broad 
polydisperse243, 244. Following this classification most of our AgNPs can be considered as moderate 
polydisperse preparations, and those prepared at 4 °C using Psychrobacter sp. broth, as near-
monodisperse. Except for AgNPs obtained with broths from P. veronii, the dispersity seems to be 
lower for preparations made at 4 °C than for those at 30 °C.  
 
 
 
 
 
 
 
 
 
 T (°C) Psychrobacter        
sp 
A.salmonicida P.veronii Y.kristensenii 
Yield(%) 
 
 
Average (nm) 
 
 
PDI 
 
 
 
 
            4 
              30 
 
               4 
              30 
 
               4 
              30 
 
 
24 
44 
 
7.6 
6.6 
 
0.1 
0.25 
 
 
 
12 
49 
 
6.2 
11.1 
 
0.17 
0.21 
 
 
38 
46 
 
5 
5.1 
 
0.23 
0.21 
 
 
 
36 
53 
 
6.1 
6.8 
 
0.18 
0.21 
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B
 
 
Figure 4.5. TEM representative images of AgNPs produced at 30 °C by the culture broths of A). Psychrobacter sp,                   
B). A. salmonicida, C). P. veronii, D). Y. kristensenii. Inserts display a higher magnification of some NPs showing crystalline 
patterns. 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4.6. TEM representative images of AgPs produced at 4 °C by the culture broths of A). Psychrobacter sp,                        
B). A. salmonicida, C). P. veronii, D). Y. kristensenii. Inserts display a higher magnification of some NPs showing crystalline 
patterns. 
A B
C D
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Figure 4.7. Distribution of AgNPs sizes obtained at 30 °C using broths from A). Psychrobacter sp, B). A. salmonicida,                
C). P. veronii, D). Y. kristensenii. 
 
Figure 4.8. Distribution of AgNPs sizes obtained at 4 °C using broths from A). Psychrobacter sp, B). A. salmonicida, C). P. veronii,  
D).Y. kristensenii. 
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   The Zeta potentials of the AgNPs were measured using a ZetasizerTM and in all cases negative values 
were obtained. This value is related with charges surrounding the particles, which provide colloidal 
stability preventing their aggregation or flocculation. Particles with high values (above 30) are stable 
for months. The highest potential was obtained from the particles prepared with the broth of            
A. salmonicida at 30 °C, and the lowest from the particles prepared at 4 °C using broths from             
P. veronii.   
 
Table 4.2. Zeta potentials (mV) of the AgNPs prepared with broths from the different bacteria at 4 °C and 30 °C. 
 
 
 
 
   To determinate the crystalline nature of the NPs obtained in the different conditions, XRD analysis 
was performed. XRD is a rapid analytical technique primarily used for phase identification of a 
crystalline material and can provide information on unit cell dimensions. XRD is based on 
constructive interference of monochromatic x-ray and a crystalline sample (Fig 4.9 and SI 2). 
   The results of this analysis showed the presence of crystalline structures in all the AgNPs, with 
similar 2θ angles for the diffraction peaks around 38.17, 43.92, 64.53, 77.45 and 81.37 degrees. 
These peaks correspond respectively to the (1 1 1), (2 0 0), (2 2 0), (3 1 1), and (2 2 2) planes of the 
face-centered cubic structure of metallic silver crystals (JCPDS file no. 04-0783). The relative intensity 
of the different Bragg reflections indicates a predominant orientation of the crystals with the (1 1 1) 
planes preferentially parallel to the supporting substrate. This predominant orientation seems to be 
higher for the AgNPs prepared at 4 °C.  
T (°C) Psychrobacter  sp A.salmonicida P.veronii Y.kristensenii 
     
               4 
              30 
 
 
 
-20.7±2.7 
-21.1±2.2 
 
 
 
-25.8±2.1 
-26.8±3.1 
 
 
 
-17.6±1.9 
-24.2±1.5 
 
 
 
-24.5±2.2 
-21.7±2.5 
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Figure 4.9. X-Ray Difraction pattern of AgNPs synthesis by broths of Psychrobacter sp A). 30 °C and B). 4 °C. 
 
4.1.3. Antibacterial activity of AgNPs 
   One of the main applications of AgNPs is their use as antimicrobial agents alone or in combination 
with other antibiotic substances. To determine whether the obtained AgNPs have antimicrobial 
activity, their corresponding antibacterial tests were performed by the dilution method15. 
Particularly, serial dilutions of the AgNPs were performed using sterile Milli-Q water down to 1/64. 
Turbidity (or Optical Density) at 550 nm was recorded every hour. In the presence of AgNPs the 
turbidity increased less than in the control showing that bacteria were growing slower due to the 
antimicrobial activity of AgNPs. IC50 was determined after 7 h. 
   Two Gram-negative (E. coli and K. pneumoniae) and one Gram-positive (S. epidermidis) from culture 
collections were evaluated at different concentrations. The results are expressed as the 
concentration required to achieve 50% of growth inhibition (IC50).  
   In general, AgNPs were more active against Gram-positive than against Gram-negative bacteria, 
and those prepared at 4 °C more active than the AgNPs obtained at 30 °C. This is more notorious with 
aged particles (incubated for 298 days), were the particles incubated at 30 °C were not active, 
whereas at 4°C were still active, particularly, those obtained from A. salmonicida supernatants with 
an IC50 > 10 µg/ml. 
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Table4.3. IC50 ( µg of Ag/ml) of AgNPs. E.c.: E. coli, K.p.: K. pneumoniae, S.e.: S. epidermidis; f: fresh prepared (9 days), o: old 
(298 days) AgNPs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T (°C) Psychrobacter sp A.salmonicida P.veronii Y.kristensenii 
        
E.c.        4  (F) 
              4  (O) 
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Figure 4.10. Antibacterial activity of AgNPs using E. coli. AgNPs used were obtained after 9 days A). at 30 °C,         
C). at 4 °C and after 298 days B). at 30 °C, D). at 4 °C. 
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Figure 4.11. Antibacterial activity of AgNPs using K.pneumoniae.  AgNPs used were obtained after 9 days             
A). at 30 °C, C). at 4 °C and after 298 days B). at 30 °C, D). at 4 °C. 
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Figure 4.12. Antibacterial activity of AgNPs in S.epidermidis. AgNPs used were obtained after 9 days A). at 30 °C, 
C). at 4 °C and after 298 days B). at 30 °C, D). at 4 °C. 
 
 
 
 
 
 
0
20
40
60
80
100
0 1 2 3 4 5 6 7 8 9 10
%
 O
f 
G
ro
w
th
 I
n
h
ib
it
io
n
Ag Concentration (µg/ml)
Psychrobacter sp
A. salmonicida
P.veronii
Y.kristensenii
A
0
20
40
60
80
100
0 1 2 3 4 5 6 7 8 9 10
%
 O
f 
G
ro
w
th
 I
n
h
ib
it
io
n
Ag Concentration (µg/ml)
Psychrobacter sp
A. salmonicida
P.veronii
Y.kristensenii
B
0
20
40
60
80
100
0 1 2 3 4 5 6 7 8 9 10
%
 O
f 
G
ro
w
th
 I
n
h
ib
it
io
n
Ag Concentration (µg/ml)
Psychrobacter sp
A. salmonicida
P.veronii
Y.kristensenii
C
0
20
40
60
80
100
0 2 4 6 8 10
%
 O
f 
G
ro
w
th
 I
n
h
ib
it
io
n
Ag Concentration (µg/ml)
Psychrobacter sp
A. salmonicida
P.veronii
Y.kristensenii
D
 73 
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4.2. DNA Silver Nanoclusters as novel nanoantibiotics 
   DNA-AgNCs are novel fluorescent materials which properties can be tuned by the selection of the 
oligonucleotides sequence employed in their elaboration. In this project we have evaluated their 
antimicrobial properties.  
 
4.2.1. Preparation and characterization of DNA-AgNCs 
   To study the antimicrobial properties of fluorescent DNA-AgNCs we selected three sequences    
(Seq-1, Seq-2 and Seq-3), which were reported before to yield emitters in the blue, yellow and red 
region244-246. 
   The oligonucleotides were prepared by standard solid-phase synthesis and purified by 
polyacrylamide gel electrophoresis (PAGE). The oligonucleotides were first mixed with six equivalents 
of AgNO3 and later with six equivalents of NaBH4 to reduce the silver salt to metallic silver. The 
samples were washed to remove the excess of reagents and then used in the different experiments. 
The generation of DNA-AgNCs was confirmed by their fluorescence spectra (Fig 4.13). 
 
Figure 4.13. Fluorescence excitation and emission spectra of AgNCs stabilized with the ONs  A). Seq1, B). Seq2 and C). Seq3. 
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   These DNA-AgNCs were incubated with E. coli and S. epidermidis and their antibacterial activity was 
evaluated using the growth curve method69 , monitoring the optical density at 650 nm. In the control 
experiment, where no antibacterial agent was added, bacteria growth was observed after 2 hours of 
incubation. However, the growth was clearly delayed when DNA-AgNCs were present in the solution  
(Fig 4.14). 
 
Figure 4.14. Growth curves in the presence of three DNA-AgNCs at 3 µM. A). in E. coli and  B). in S. epidermidis. The 
experiments were done in triplicates and the error bars represent the standard deviation.  
   This behavior was confirmed using a complementary method to evaluate the antimicrobial activity, 
the Kirby-Bauer disk diffusion susceptibility test247. In this test a paper disk containing the reagent is 
placed on an agar plate where bacteria can grow. The reagent from the disk diffuses and prevents the 
growth of the bacteria around it, leaving a clear inhibition area (Figure 4.15). As in the previous 
method the Seq-3 showed the best antimicrobial activity. 
 
 
Figure 4.15. Kirby-Bauer disk diffusion susceptibility test. A). Control B). Seq-1 C). Seq-2 D). Seq-3. The antibacterial effect is 
confirmed by the presence of a clear zone surrounding the disks with DNA-AgNCs. 
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   Then, the amount of silver in each sample was quantified, since it could be related with the activity 
observed. The quantification by TXRF revealed that AgNCs stabilized with Seq-1 have more silver 
than the other two derivatives (Fig 4.16). 
 
Figure 4.16. Quantification of silver of the DNA-AgNCs by TXRF. The data showed is the average of three independent 
measurements. 
   Then, additional sequences were evaluated aiming to find a relationship between the sequences 
and their antimicrobial activity. The sequences employed yielded emitters in the blue, yellow and red 
region and are summarized in Table 4.4. 
Table 4.4. Sequences employed in the preparation of AgNCs. 
  
 
 
 
 
 
 
 
 
 
 
Name Sequence 
Seq-1 
 
Seq-2 
 
Seq-3 
 
Seq-4 
 
Seq-5 
 
Seq-6 
 
Seq-7 
 
Seq-8 
 
Seq-9 
 
Trimer (Seq-3) 
5´-TTTTCCCCTTTT-3´ 
 
5´-CCCTTAATCCCC-3´ 
 
5´-CCCCCCCCCCCC-3´ 
 
5´-CCCTTTAACCCC-3´ 
 
5´-CCCCTTTTCCCC-3´ 
 
5´-GGGTTAGGGTCCCCCCACCCTTACCC -3´ 
 
5´-GGGTGGGTCCCCCCACCCACCC -3´ 
 
5´-CCTCCTTCCTCC -3´ 
 
5´-AGGTCGCCGCCC  -3´ 
 
(5´-CCCCCCCCCCCC-3´)3-Benzene 
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  Then, the antimicrobial activity of the DNA-AgNCs was evaluated as before. All the samples showed 
some antimicrobial activity, which varies depending on the sequence employed (Fig 4.17). However, 
there is not a clear correlation between the sequence employed and the activity, observed.  
 
 
Figure 4.17. E. coli and S. epidermidis growth curves in the presence of DNA-AgNCs at 3µM. 
E.coli: A). Blue emitters B). Yellow emitters, and C). Red emitters. S. epidermidis: D). Blue emitters, E). Yellow emitters and 
F). Red emitters. 
 
   Cytosines are known to bind tighter to silver than other nucleobases, and therefore they might 
modulate the antimicrobial activity. Unfortunately, we could not find a clear correlation between the 
activity and the number of cytosines (Fig. 4.18). For instance, Seq-3, Seq-6 and Seq-7 have the same 
amount of cytosines but different antimicrobial activity. On the other hand, Seq-2 has less cytosines 
than Seq-5, Seq-6, Seq-7, and Seq-8 but has better antimicrobial activity. 
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Figure 4.18. Representation of antimicrobial activity and number of cytosines for each samples. 
 
   On the other hand, when the three different groups of emitters are compared it seems clear that blue 
emitters have the lowest activity (Fig 4.17 A and 4.17 D), whereas yellow (Fig 4.17 B and 4.17 E) and red 
emitters (Fig 4.17 C and 4.17 F) showed similar activity, where the red emitter obtained with Seq-3 
showed the best activity. 
   Since the amount of silver or the sequence cannot explain completely the differences in activity we 
wondered if the structure of the complexes generated could play a role. For this reason we carried out 
CD studies to compare their structure using Seq-1, Seq-2 and Seq-3 (Fig 4.19). Thus, we look at the 
structures before and after the formation of the DNA-AgNCs at different temperatures. In the case of 
Seq-1 the CD showed the characteristic peaks of an unfolded DNA strand with a positive band at 280 and 
a negative one around 255 (Fig. 4.19 A). In this case the temperature did not affect significantly the 
spectra since the strand was already unfolded. After the formation of AgNCs those bands decreased 
considerably (Fig 4.19 B). 
   On the other hand, Seq-2 and Seq-3 showed the characteristic peaks of an i-motif with a dominant 
positive band around 290 nm and negative one close to 260 nm (Fig 4.19 C and 4.19 E) . These i-motif 
structures where destabilized as the temperature increases to yield the standard arrangement for DNA, 
with a positive band at 280 and a negative one at 255. In the case of Seq-2, the i-motif was denatured at 
lower temperatures compared with Seq-3. In this case the structure was unfolded at 55 °C, whereas  
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Seq-3 required temperatures up to 75 °C to completely unfold the i-motif. In both cases the generation 
of AgNCs induced great changes in the CD spectra, with negative bands around 215 and 270 and positive 
one near 240 (Fig 4.19 D and 4.19 f). In the case of Seq-3 the bands were more pronounced and the 
band at 290 characteristic of i-motif disappeared completely. It is remarkable the high stability of the 
structures obtained with both sequences, which CD did not change along the different temperatures 
tested (Fig 4.19). 
 
 
 
Figure 4.19. CD of the samples Seq-1, Seq-2 and Seq-3 before (A, C and E respectively) and after (B, D and F respectively) 
the generation of AgNCs. 
 
   Besides these considerations, the sample that yielded the higher activity was Seq-3 and for this 
reason we continued our studies using this derivative. First, we carried out a dose-response study 
using 5 different concentrations as illustrated in (Fig 4.20). 
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   Inhibition of bacterial growth showed a clear dose-dependent response, where the higher the 
concentration of the DNA-AgNCs employed, the larger the antimicrobial inhibition activity. Using the 
highest concentration (5 µM) the DNA-AgNCs were able to suppress the growth of the bacteria for 14 
hours.  
 
Figure 4.20. A). E.Coli and, B). S.epidermidis growth curves in the presence of AgNCs stabilized with Seq-3 at different 
concentrations. 
   Then, we compared the activity of this derivative with related silver species, such as silver cations 
and AgNPs, which are known to have antibacterial activity. We employed the AgNO3 used in the 
preparation of AgNCs as a source of silver cations. AgNPs were prepared by reduction of AgNO3 with 
NaBH4, following the same procedure as for the preparation of AgNCs, but without the addition of 
DNA. The same amount of AgNO3 was used in the preparation of the three samples. As shown in (Fig 
4.21), AgNCs stabilized with sequence 3 and AgNO3 were found to have better activity than AgNPs.   
 
Figure 4.21. Growth curves in the presence of AgNCs stabilized with Seq-3 at 3 µM, AgNPs and AgNO3 in A). E. coli and      
B). S. epidermidis. The concentration of silver in all samples was 9.8 µM. The experiments where done in triplicates and the 
error bars represents standard deviation. 
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   Finally, motivated by the good properties of the AgNCs generated with the Seq-3 as antibacterial 
agent, a derivative with increased inhibitory activity was designed. Our research groups has recently 
reported the use of oligonucleotides trimers in the preparation of AgNCs, which have shown 
increased fluorescence and stability146. Thus, we planned to use the same strategy to prepare a trimer 
that could yield AgNCs with better antimicrobial activity.  
   For this purpose a click reaction between a benzene derivative bearing three azides and the Seq-3 
modified with an alkyne group was carried out.  
N3
N3N3
Seq-3-Alkyne
CuI, 55 ºC, 16 h
N
NN
N
N
N
NN
N
Seq-3
Seq-3
Seq-3
 
   The resulting trimer was purified by gel electrophoresis and used in the preparation of AgNCs. 
Incubation of this compound with AgNO3 followed by reduction with NaBH4 yielded the 
corresponding fluorescent AgNCs.  
   AgNCs stabilized with the trimer system showed excellent inhibition of bacteria growth at low 
concentration (0.750 µM or 1.5 µM) and even killing all bacteria at 2.25 µM (Fig 4.22). 
 
 
Figure 4.22. Bacteria growth inhibited by the presence of the DNA-AgNCs stabilized by trimers prepared with Seq-3 at 
different concentrations in A). E. coli and B). S. epidermidis. 
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   Regarding the mechanism of action of these derivatives, it is not completely clear and multiple 
mechanism could be involved. For instance, silver salts can inhibit some key enzymes, reduce the level 
of antioxidants, disrupt the cell membrane and increase the amount of ROS. The later one is the most 
general process implicated in the antibacterial properties of silver derivatives. For this reason we 
checked the production of ROS using the fluorescent probe 2´,7´-dichlorodihydrofluorescin diacetate 
(DCFH-DA). ROS production was evaluated in E. coli and S. epidermidis bacteria after the incubation of 
DNA-AgNCs for 14 hours in the dark. The results showed an increase in ROS production when DNA 
AgNCs were present (Fig 4.23). 
 
Figure 4.23. Seq-3 DNA-AgNCs enhanced to the ROS production in A). E. coli and B). S. epidermidis. 
 
4.3. Photodynamic Therapy using Photosensitizers conjugated to oligonucleotides 
 
4.3.1. Characterization of oligonucleotides modified with Photosensitizers 
   PDT is a promising method for the control and treatment of infectious diseases that utilizes light-
sensitive molecules known as photosensitizer (PS). When these derivatives are excited with the light, 
the amount of ROS is increased, which can induce the death of the cells. One of the main advantages 
of PDT compared to traditional approaches is that bacteria are less prone to develop resistance after 
therapy 190 . 
   In this case we decided to explore the effect of PS conjugated to oligonucleotides and later 
combine them with AgNCs. We decided to use the sequences Seq-2, Seq-3, Seq-7 and Seq-8, 
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previously employed in the preparation of AgNCs and the derivative of fluorescein,                               
5-hexachlorofluorescein (HEX), as a PS. 
   Only the first three sequences were labeled with HEX, and Seq-8 was used as control to assess the 
role of the PS. The samples were labeled as PS1, PS2, PS3 and Control respectively in the 
experiments. The system was evaluated against Gram-positive (Staphylococcus aureus) and Gram-
negative (Escherichia coli and Pseudomonas aeruginosa) bacteria. 
   The absorption spectra of purified oligonucleotides modified with HEX (PS1, PS2 and PS3), showed 
two representative peaks, one at 260 nm (oligonucleotides) and other at 540 nm (HEX) (Fig 4.24). The 
control strand (Control) only showed the characteristic peak at 260 nm. oligonucleotides were also 
analyzed by MALDI-TOF (Table 4.5). 
 
Figure 4.24. UV-Vis absorption spectra of oligonucleotides employed. 
 
Table 4.5. MALDI-TOF of the oligonucleotides. 
 
Name Sequence               Calculated mass Found 
PS1 
 
PS2 
 
PS3 
5´-HEX- CCCTTAATCCCC-3´ 
 
5´-HEX- CCCCCCCCCCCC-3´ 
 
5´-HEX- GGGTGGGTCCCCCCACCCACCC -3´ 
 
4245.43 
 
4152.33 
 
7362.43 
4245.10 
 
4152.08 
 
7360.21 
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   The fluorescence intensity of the sequences (PS1, PS2 and PS3) was recorded at the same 
concentration of the oligonucleotides as well as the fluorescence of the AgNCs obtained with them. 
The fluorescence intensity due to the HEX, with and without AgNCs, showed the following order:   
PS3 > PS1 > PS2 (Fig 4.25). 
 
 
Figure 4.25. Fluorescence intensity of ONs –HEX and ONs-HEX-AgNCs obtained after 16h. 
 (ex/em: 536 / 557 nm) (Control= Seq-8) 
 
 4.3.2. Antibacterial activity 
   The susceptibility of the E. coli, S. aureus and P. aeruginosa to these systems was determined by 
the growth curve method (Materials and Methods 3.11.3 ). A light source, with a maximum at        
525 nm, was employed during two hours to induce the production of ROS and then the samples were 
incubated at 37 °C for 20 h under mild shaking. The OD measured at 650 nm was used to monitor the 
bacteria growth. In the case of PS1 the bacteria growth was significantly inhibited at 0.750 and        
1.5 µM in S. aureus and E. coli., when the light system was applied (Fig 4.26 A and Fig 4.26 B). 
Surprisingly, when the concentration employed was increased (3 µM) the antimicrobial activity 
disappeared (Fig 4.26). 
 
 
 
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
PS1 PS2 PS3 Control
Fl
u
o
re
sc
e
n
ce
 In
te
n
si
ty
Samples
Without AgNCs
With AgNCs
        84 
 
4 RESULTS 
 
 
 
 
 
 
 
Figure 4.26. Optical density of bacteria cultures incubated with PS1 at different concentrations. A,D). S. aureus, B,E). E. coli 
and C,F). P. aeruginosa. A decrease in the optical density is associated with antibacterial activity. A,B,C with irradiation and 
D,E,F, without irradiation. 
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   In the case of PS2, good antibacterial activity was observed against S. aureus at 0.750 µM             
(Fig 4.27 A) and against E. coli at 0.750 µM and 1.5 µM (Fig 4.27 B), after light irradiation. 
Remarkably, PS2 showed some activity even in the dark against E. coli (Fig 4.27 E). 
 
 
 
 
 
Figure 4.27. Optical density of bacteria cultures incubated with PS2 at different concentrations. A,D). S. aureus, B,E). E. coli 
and C,F). P. aeruginosa. A decrease in the optical density is associated with antibacterial activity. A,B,C with irradiation and 
D,E,F, without irradiation. 
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   PS3 showed significant antibacterial activity against S. aureus at low concentration (0.750 µM)    
(Fig 4.28 A). However, in the other cases the antimicrobial effect was not that clear. 
 
 
 
 
 
Figure 4.28. Optical density of bacteria cultures incubated with PS3 at different concentrations. A,D). S. aureus, B,E). E. coli 
and C,F). P. aeruginosa. A decrease in the optical density is associated with antibacterial activity. A,B,C with irradiation and 
D,E,F, without irradiation. 
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 The control sequence did not show any antimicrobial activity with or without the light system        
(Fig 4.29). 
 
 
 
 
 
Figure 4.29. Optical density of bacteria cultures incubated with Control at different concentrations. A,D). S. aureus, B,E).     
E. coli and C,F). P. aeruginosa. A decrease in the optical density is associated with antibacterial activity. A,B,C with 
irradiation and D,E,F, without irradiation. 
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   These results point out that the systems are active against Gram-positive and Gram-negative 
bacteria, however the results depend on the sequences and bacteria employed, as illustrated in      
Fig 4.30, where the activity of the three systems and bacteria are compared after 20 h at 0.750 µM. 
 
 
 
Figure 4.30. Optical density obtained from bacteria treated with the oligonucleotides and light at 0.750 µM after 20 h. 
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  Then, we decided to evaluate the effect on the antimicrobial activity of this system in combination 
with the formation of AgNCs. When PS1-AgNCs was employed a good antimicrobial activity was 
observed against S. aureus and E. coli at 0.750 µM and 1.5 µM, after the light irradiation (Fig 4.31). In 
this case, some activity was also observed in the dark, due to the presence of AgNCs (Fig 4.31 E). 
 
 
 
 
Figure 4.31. Optical density of bacteria cultures incubated with PS1-AgNCs at different concentrations. A,D). S. aureus, B,E). 
E. coli and C,F). P. aeruginosa. A decrease in the optical density is associated with antibacterial activity. A,B,C with 
irradiation and D,E,F, without irradiation. 
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   In the case of PS2-AgNCs good antibacterial activity was observed against E. coli at every 
concentration when the light system was applied (Fig 4.32). 
 
 
 
 
 
 
Figure 4.32. Optical density of bacteria cultures incubated with PS2-AgNCs at different concentrations. A,D). S. aureus, B,E). 
E. coli and C,F). P. aeruginosa. A decrease in the optical density is associated with antibacterial activity. A,B,C with 
irradiation and D,E,F, without irradiation. 
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   PS3-AgNCs showed good antibacterial activity against S. aureus at 0.750 and 1.5 µM, with 
irradiation (Fig 4.33 A). In the other cases the antimicrobial effect was not so clear. 
 
 
 
 
 
 
Figure 4.33. Optical density of bacteria cultures incubated with PS2-AgNCs at different concentrations. A,D). S. aureus, B,E). 
E. coli and C,F). P. aeruginosa. A decrease in the optical density is associated with antibacterial activity. A,B,C with 
irradiation and D,E,F, without irradiation. 
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4.3.3. ROS 
   Finally, we evaluated the production of ROS by PS1 when the light system was used in S. aureus  
(Fig 4.34). The experiments revealed that ROS production is increased at 0.750 µM and 1.5 µM but 
not at 3 µM. These results are in agreement with the antibacterial activity observed where at 3 µM 
the system is not active (Fig 4.26 A) Thus, one of the mechanism involved in the antimicrobial activity 
of PS1, and probably in the other systems, is the production of ROS.   
 
 
 
Figure 4.34. PS1 ROS generation in the S. aureus. 
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4.4. p21 regulation with oligonucleotides conjugated to gold nanoparticles 
 
   Antisense oligonucleotides have been used for a number of years to modify the expression of 
specific genes both in vivo and in vitro248, 249. The main limitations in this kind of approaches are the 
efficient delivery of the oligonucleotides into the target cells, and their stability. To overcome these 
limitations we are exploring the use of AuNPs as delivery systems of different oligonucleotides 
(antisense and siRNA) in the regulation of p21.  
   Particularly we have evaluated two antisenses, one Gapmer and one siRNA. The sequences 
employed in these experiments are summarized in Table 4.6. They were prepared with a dithiolane 
group at the 3’-end to ease the conjugation with AuNPs. A nonsense sequence (NS) was employed as 
control in the experiments. 
 
Table 4.6. Functional oligonucleotides evaluated to control p21 gene expression. 
 
Name Sequence 
Antisense-1 
 
Antisense-2 
 
Gapmer 
 
siRNA      
Passenger (Sense)  
Guide (Antisense)                                           
5´-AGA CAA CGG CAC ACU UUG C-TTTTT-3´ 
 
5´-AUA GAA AUC UGU CAG GCU G-TTTTT-3´ 
 
5´-GAU AGA AAT CTG TCA GGC UG-3´ 
 
 
5´-CAG CCU GAC AGA UUU CUA U-TTTTT-3´ 
5´-AUA GAA AUC UGU CAG GCU G-TT-3´ 
 
  
 
   First, we evaluated the inhibition activity of AuNPs modified with the oligonucleotides using 
Western blot. We observed that after stimulation with Con A of CD4+ positive T-cells and incubation 
with AuNPs modified with antisense 1 and 2 the p21 expression decreased after 2 hours (Fig 4.35 A). 
This effect was slightly more intense when antisense 2 was employed, for this reason the next 
experiments were done with this sequence. We also found that the inhibition of p21 was more 
effective at short times (Fig 4.35 B). 
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   Amaxa kit was used to transfect Antisense 2 in the same concentration following the procedure 
provided by the manufacturer to compare the inhibition. In this case the effect of antisense 2 was 
observed after 14 hours (Fig 4.35 C).  
 
 
Figure 4.35. Western Blot of different proteins from T Cells treated with antisense and nonsense oligonucleotides 
internalized by A). Modified AuNPs B). Modified AuNPs at short times. C). Amaxa kit. 
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   Then, the effect of the sequence employed in antisense 2 with a Gapmer desing was evaluated. This 
design could provide better activity since the interaction with RNAase H is more efficient than in the 
previous case. Particularly the inhibition was observed up to 1.5 hours (Fig 4.36). 
 
Figure 4.36. T-cells treated with Gapmer-AuNPs at different time points.  
 
   Besides the western blot, we used flow cytometry to quantify the transfection efficiency of the 
oligonucleotides using AuNPs and the Amaxa kit after 24 and 48 hours. The results obtained revealed 
that the transfection efficiency mediated by AuNPs was 32.7% and 44.6% after 24 and 48 hours, 
respectively (Fig 4.37 A). Whereas using the Amaxa kit the efficiency was 49.9% and 62.3% after 24 
and 48 hours, respectively (Fig 4.37 B). 
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Figure 4.37. T-cells transfection efficiency measured by Flow cytometry using A). Antisense2-AuNPs, B). Antisense2-Amaxa 
kit. 
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   Then, we evaluated the effect of AuNPs modified with siRNAs against p21, which were able to 
reduce the expression of the protein. 
   AuNPs modified with siRNA (at 120 nM) were incubated with T-cells at different time points. The 
western blot revealed that expression of p21 is decreased up to one hour (Fig 4.38 A) and the 
expression is recovered during the following hours (Fig 4.38 B). When higher concentration of AuNPs-
siRNAs (150 nM) was employed the expression of p21 was affected even after 4 h (Fig 4.38 C). 
Figure 4.38. Western blot of T-cells treated with AuNPs modified with siRNAs against p21. A, B). 120nM and C). 150 nM. 
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                                                                                                                                                        DISCUSSION 
 
5.1. Nanotechnology and Antibiotic Resistance Bacteria 
   The discovery and implementation of antibiotics in the early twentieth century transformed 
human health and wellbeing. However, the emergence of pathogenic bacteria resistant to 
many or all current antibiotics is currently a major public health concern and of particular 
importance in clinical settings. Nowadays, advanced technologies based in biotechnology and 
nanotechnology have a great potential to tackle this problem. In this sense, silver-based 
nanomaterials, such as AgNPs, have shown remarkable antimicrobial properties and are used 
in multiple applications. The work presented in this thesis was motivated by the excellent 
properties of AgNPs and has been focused in the development of a green process for the 
production of AgNPs as well as the development of novel nanoantibiotics based on DNA-
AgNCs. In addition, the preliminary results of a collaboration where different oligonucleotides 
are used to control the gene expression of p21 in T-cell has been included as well. The first part 
of this thesis was carried out within the Biology Department at Universidad Autónoma de 
Madrid and the others at IMDEA Nanociencia. Below is included the discussion of the four 
topics addressed in this thesis. 
  
5.2. Synthesis and antimicrobial activity of silver nanoparticles generated with Antarctic 
bacteria broths 
 
   AgNPs can be produced using different bacteria extracts, however, Antarctic bacteria have 
not been employed so far, and their broths might be very different compared with other 
species. In this work, in this case, the effect of light, temperature and salt concentration in the 
generation of AgNPs has been studied.  
   The production of AgNPs using bacteria broths was followed by UV–vis spectroscopy, 
showing a progressive increase in the absorbance at 450 nm due to the formation of AgNPs at 
4 ˚C and 30 ˚C, but only when the incubation was carried out under the light (Figure 4.1). In 
addition, when NaCl was added to the reaction mixture, the yield decreased significantly 
(Figure 4.2)68. Several reports have shown a negative effect due to the presence of Cl-250,251, 
although others demonstrated that AgCl can be employed in the synthesis of AgNPs238.  
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   In this case the production of AgNPs was reduced in the presence of NaCl (5 g/l, 85.5 mM), 
particularly, at 4 °C. Thus we can conclude that, the presence of NaCl is deleterious for AgNPs 
production during the preparation of the broths from psychrophilic bacteria, despite growing 
in salty areas (Figure 4.2). In this experiments the highest yield was obtained using broths from 
Y. kristensenii at  30 °C, and the lowest using A. salmonicida at 4 °C (Table 4.1). 
   The sizes of the AgNPs obtained by the different bacteria were similar (around 6 nm), with 
the exception of the AgNPs produced at 30 °C using broths from A. salmonicida, which were 
noticeably larger (11.1 nm).  
   Size distributions for the different AgNPs obtained are shown as histograms in figure 4.7 and 
4. 8. The PDI of the AgNPs obtained was around 0.2 in most cases (Table 4.1).  
   A PDI of 0.0 corresponds to monodisperse AgNPs, up to 0.1 AgNPs are considered as near   
(or narrow) monodisperse, from 0.1 to 0.4 AgNPs are moderate polydisperse, and values >0.4 
indicate high polydispersity.  
   The highest (0.25) and lowest (0.1) PDI were obtained when broths from Psychrobacter sp. 
were employed at 30 °C and 4 °C, respectively (Table 4.1). In general the PDI was lower when 
the reaction was carried out at 4 °C. In the case of P. veronii the PDI was almost the same 
under both conditions.  
   The zeta potentials of the AgNPs obtained by this method were negative (Table 4.1). In this 
case, the highest potential was obtained at 30 °C using broths form A. salmonicida (-26.8 + 3.1) 
and the lowest at 4 °C using broths from P. veronii (-17.6 + 1.9).  
   The zeta potential is usually employed to predict the colloidal stability of NPs, and it 
correlates well in the case of P. veronii, which UV-Vis spectra show a significant drop in the 
intensity when the particles where aged for 10 months compared with particles obtained after 
9 days (Fig. 4.4 C).   
   The antibacterial activity of AgNPs obtained in this thesis was tested in three bacteria from 
culture collections, two Gram-negative (E. coli and K. pneumoniae) and one Gram-positive      
(S. epidermidis). In general, AgNPs were more active against Gram-positive than against Gram-
negative bacteria and more active when prepared at 4 °C than those obtained at 30 °C      
(Table 4.3). However, AgNPs obtained using A. salmonicida broths showed lower activity when 
prepared at 4 °C than when obtained at 30 °C, highlighting the importance of the broth 
employed. Indeed, the particles obtained from broths of this bacteria showed the highest 
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antimicrobial activity against E. coli and K. pneumoniae, and an excellent activity against           
S. epidermidis. 
   Regarding the mechanism of action of AgNPs the release of silver ions seems to be critical in 
the activity of AgNPs,38 although their interaction with the bacteria cell envelopes have to be 
considered as well252,253. In this regard, the decrease in activity of aged AgNPs could be related 
to the generation of a corona surrounding the particle254, which can prevent the release of 
silver ions and/or disrupt the interaction with the bacteria. Thus, the interaction between the 
AgNPs and bacteria will depend not only on the size, surface or surface/volume ratio of the NPs 
but also on the composition of the corona.   
   In this regard, it is worth mentioning that the UV–vis spectra of the AgNPs kept for 10 months 
(at 4 °C and 30 °C) did not change much in most cases (Fig 4.3 and 4.4), however their 
antimicrobial activities showed significant variations. Particularly, it decreased against the 
Gram-negative bacteria tested and increased slightly against S. epidermidis when kept at 4 °C 
(Fig 4.12).   
   In addition, AgNPs prepared at 4 °C using broths from A. salmonicida reported different 
behavior depending on the bacteria tested. Particularly, the aging process decreased their 
activity against E. coli but increased it against K. pneumoniae. However, in the case of AgNPs 
obtained from Y. kristensenii broths at 4 °C, the effect of aging in the activity turned to be the 
other way around, where the aged ones were more active against E. coli and less active against 
K. pneumoniae.  
   This phenomenon may be due to a combination of the different envelopes present in the 
species and the different corona surrounding the AgNPs. These results stress out the need for 
standardizing the bacteria tested in this kind of studies since differences can be observed not 
only among Gram-negative and Gram-positive bacteria but also depending on the particular 
species and also on the strain used as highlighted recently255.  
   The activity of commercial available AgNPs stabilized with citrate was also evaluated at       
8.5 µg/ml affording inhibition of 59.6%, 42.5% and 36.1% for E. coli, S. epidermidis and               
K. pneumoniae, respectively. Remarkably, the AgNPs prepared herein using broths from 
different bacteria showed more than 80% of inhibition at the same concentration in every 
bacteria. These results highlight the importance of the methods employed in the preparation 
of AgNPs to achieve good antimicrobials. 
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5.3.DNA silver nanoclusters as novel nanoantibiotics 
   DNA-AgNCs have recently emerged as new materials with interesting fluorescent properties, 
since they are more stable to photobleaching than organic dyes an smaller than quantum dots 
or fluorescent proteins. They contain few atoms of silver (2-10) and have a small size (<2 nm), 
close to the Fermi distance, that makes them fluorescent materials.  
   One of the most striking characteristics of DNA-AgNCs is the tunability of their fluorescent 
properties, which is an indication for the specific arrangement of the silver atoms256,257. In this 
sense, it is possible to modulate their excitation and emission wavelength by the sequence of 
the oligonucleotides employed in their preparation. Although the fluorescent properties of 
DNA-AgNCs cannot be predicted, emitters from the blue to the near-infrared have been 
reported, depending on the oligonucleotides sequence258,259.  
   On the other hand the use of silver materials to treat bacterial infections is as old as history, 
however, DNA-AgNCs have not been evaluated before and their tunability by oligonucleotides 
could make them an interesting platform for the development of novel nanoantibiotics.  
   Among the first sequences tested, Seq-1, Seq-2 and Seq-3, the later one showed the best 
antimicrobial activity. This result could be explained by the differences of silver bound to the 
oligonucleotides, since cytosines bind silver better than other nucleobases135 and Seq-3 has 
higher number of cytosines. However, quantification of silver in the different samples using 
TRXF revealed that Seq-1 contained more silver than the other derivatives and Seq-2 and Seq-3 
contained almost the same amount (Fig 4.16). These results indicate that the activity of DNA-
AgNCs is not only due to the presence of silver and other factors might modulate the 
antibacterial effect (e.g. sequence, structure). 
   Thus, additional sequences were evaluated to shed some light on the behavior observed (Fig. 
4.17). The sequences were grouped by the emission color and although there is not a clear 
correlation between the sequence and the activity, it seems that blue emitters have the lowest 
activity, whereas yellow and red emitters have good antimicrobial activity. The amount of 
cytosines does not play any significant role, since sequences with the same number of 
cytosines have different activity (Fig 4.18). 
   Since we could not explain the different activity based on the sequence or the silver content 
we explored if it might be related with the structure and stability of the DNA-AgNCs. It is known 
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that the fluorescence properties of the AgNCs are strongly affected by their structure and 
environment41 and we wonder if a similar behavior could be found in the case of their 
antibacterial activity. For this reason, CD studies were carried out to compare the structure and 
stability before and after the formation of the DNA-AgNCs at different temperatures (Fig 4.19). 
   The results revealed that Seq-2 and Seq-3 are folded into a secondary structure, such as an    
i-motif, before the generation of AgNCs. What is more, the new structures generated with 
these oligonucleotides after the formation of AgNCs are very robust since they do not change 
when heated at 75 °C. Interestingly, the CD spectra of the three samples evaluated revealed a 
pattern that match the antibiotic activity observed. It seems that as the derivatives are more 
structured they are more active (Fig 4.19B, 4.19D and 4.19F). The derivative obtained with   
Seq-3 presents larger CD signals at 220 nm and 270 nm, whereas the intensity obtained with 
Seq-2 is smaller and in the case of Seq-1 there is no significant CD signal. The prominent bands 
in Seq-3 DNA-AgNCs suggest a more structured conformation than for the other two and this 
difference might be related to the different activities observed. For instance, this nanostructure 
may interact better with the cell membrane and even improve the uptake of AgNCs260. 
   The Seq-3 was used in further studies, such as a dose-dependent experiment and a 
comparative study against other silver derivatives. DNA-AgNCs stabilized with Seq-3 showed a 
nice dose-dependent response, which were able to suppress the growth of E. coli at 5 µM for at 
least 14 hours. However, at this concentration the system was only able to delay the growth up 
to 7 hours in S. epidermidis (Fig 4.20). 
   When the derivative was compared to silver salts or AgNPs, it showed a good activity, which 
was similar to silver nitrate in E. coli and less active than silver nitrate but better than AgNPs in 
S. epidermidis. 
   The excellent activity obtained with DNA-AgNCs might be due the combination of different 
mechanisms of action, such as, the intercalation of AgNCs in the DNA and the release of silver 
cations. 
   Motivated by the good properties of the AgNCs generated with the Seq-3 as antibacterial 
agent, we decided to prepare a modified derivative aiming to increase their inhibitory activity. 
Particularly, we wanted to evaluate the use of trimers, previouly reported by our group, in the 
stabilization of AgNCs as antimicrobials. This system has been used to obtain AgNCs with 
increased stability and fluorescence and it might also increase their antimicrobial activity. 
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Indeed, the AgNCs estabilized with the trimer showed excellent antimicrobial activity in both 
bacterias (Fig 4.22). The enhancement of the antimicrobial activity was more notorious in the 
case of S. epidermidis since at 0.750 µM the inhibition of the trimer was better (5 hrs) than 
when the single stranded system was used at 2.25 µM (3 hrs). 
   Finally, the role of DNA-AgNCs in the production of ROS was investigated using the 
fluorescent probe DCFH-DA in E. coli and S. epidermidis (Fig. 4.23). The production of ROS was 
clearly enhanced in the presence of DNA-AgNCs, pointing out that, at least, this is one of the 
mechanisms of action of DNA-AgNCs as antimicrobials.  
 
5.4. Modified oligonucleotides in photodynamic therapy for bacteria growth control 
   PDT is being applied in the last years for the treatment of infectious diseases and superficial 
tumors261, 262. The technique involves the excitation with light of special molecules known as 
photosensitizers (PS), close to the target cells (e.g. bacteria, cancer cells). This process 
generates reactive oxygen species, which induce the death of the surrounding cells263. 
   In this section we evaluated the use of oligonucleotides modified with the fluorescent dye    
6-carboxy-2´,4,4´,5´,7,7´-hexachloro fluorescein (HEX) in PDT against bacteria.  
   Four different oligonucleotides were employed in this study, particularly, Seq-2, Seq-3 and 
Seq-7, which were conjugated with HEX, and Seq-8 used as control. In addition, these ONs-HEX 
were also employed in the preparation of AgNCs. The antibacterial activity of the system was 
assessed using two Gram-negative (E. coli and P. aeruginosa) and one Gram-positive (S. aureus) 
bacteria.  
   The cell wall of Gram-positive bacteria presents a thick and porous cell wall of inter-
connected peptidoglycan layers that surround a cytoplasmic membrane254,264, Gram-negative 
bacteria have an outer membrane, a thinner peptidoglycan layer and a cytoplasmic 
membrane254. 
   The mechanism of action of PDT requires that the PS penetrates the cell walls 265 of the 
bacteria and end up in the plasma membrane or in the cytoplasm, however, the membrane 
barriers of the bacterial cell limit the simple diffusion of PS into the bacterial cytosol266. For this 
reason, Gram-positive bacteria are more sensitive to PDT than Gram-negative bacteria267. 
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5 DISCUSSION 
   In our experiments with Seq-2, Seq-3, and Seq-7 containing HEX, and further modified by 
AgNCs where employed at 0.750, 1.5, and 3 µM. All samples reported good antibacterial 
activity when irradiated and employed at low concentration (Fig 4.26 and 4.31). However, when 
the oligonucleotides where employed at high concentration (3µM) the activity dropped 
significantly. This might be due to a self-quenching processes of HEX, which can be enhanced as 
the concentration increases268.  
   We also observed different sensitivity of our bacterial strains to our system, which might be 
related to the different bacterial cell wall structure, as mentioned before. 
 
5.5. Regulation of p21 by oligonucleotides conjugated to gold nanoparticles 
   Oligonucleotides can be used to control the expression of genes using different strategies, 
such as Antisense269, Gapmer270, and siRNA213,214. 
   Antisense oligonucleotides are short and single stranded which are complementary to 
specific mRNA transcripts that promote the degradation of target mRNA by RNase H or by 
forming a stable DNA-RNA duplex. To elicit RNase H activation, chimera oligonucleotides with a 
DNA region and modified ribonucleotide regions are generally utilized as the antisense strands. 
These chimera oligonucleotides, named “Gapmer”, have wing regions consisting of modified 
ribonucleotides such as 2´-OMe RNA at both sides and a window region in the center consisting 
of DNA residues271,272. 
   siRNAs are double stranded molecules, consisting of a guide strand that is perfectly 
complementary to a target mRNA and a passenger strand. The RNA duplex is recognized by a 
RISC complex, which will release the passenger strand and will use the guide one to find the 
target sequence in the cytoplasm.  
   However, one limitation of the use of oligonucleotides in vitro and in vivo is they low stability 
and poor translocation efficiencies. For this reason multiple approaches addressing this 
limitation are being developed.  
   For the delivery of nucleic acids, several lipid-based vectors (e.g., Transfectam273 and 
Lipofectamine274) are available. However, despite their good transfection efficacy in cell 
culture, they have several limitations in clinical applications, e.g., toxicity, low storage stability, 
lack of targeting efficacy, and limited in vivo tracking/monitoring.  
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5 DISCUSSION 
   On the other hand, electroporation systems like the Amaxa kit employed here are expensive 
and a large amount of cells die during the process.  
   For these reasons, novel delivery systems such as AuNPs might be a good alternative to 
overcome the limitations of the current transfection systems. Particularly, AuNPs can be 
fabricated with low size dispersity275 modified easily with a variety of molecules276,277 , have 
very low toxicity278,279 , good biodistribution280,281 and can be excreted282,283. 
   In this study, cyclin-dependent kinase inhibitor p21 was targeted by Antisense, Gapmer, and 
siRNA, using AuNPs as delivery system. Flow cytometry (Fluorescence-Activated Cell Sorting, 
FACS) was used to assess the transfection efficiency, showing that transfection efficiency 
mediated by AuNPs was 32.7% after 24 hours, while using the Amaxa kit was 49.9% (Fig.4.37). 
Importantly, using AuNPs, we observed a decrease in p21 expression as early as 1 hour after 
secondary stimulation (Fig 4.35 B). This difference could be related to the mechanism of AuNPs 
and Amaxa kit delivery systems, where the later might release the oligonucleotides slower   
(Fig 4.35 C).  
   The inhibition observed with the NPs modified with antisense 1 and 2 was very poor. 
However, we observed better inhibition in the case of antisense 2 and for this reason we 
employed this sequence in the preparation of other type of antisense (Gapmer) and a siRNA. 
   AuNPs modified with gapmer were able to decrease the expression of p21 after 1 h better 
than the previous antisense employed (Fig 4.36).  
   In the case of AuNPs functionalized with siRNAs the reduction of the expression was higher 
than in the previous cases. Particularly when the concentration was 120 nM the decrease in 
the expression was observed up to 1 h, and when the concentration employed was 150 nM the 
inhibition was maintained after 4 hrs (Fig 4.38). 
   Our data showed that the use of AuNPs as delivery systems of oligonucleotides in T-cells is 
very convenient since the system induces minimal death and leads to a very early reduction of 
the target protein. These characteristic are very important for systems where manipulation of 
a target protein should be rapid. This is the case for activation of T-cells, which occurs within 
the first hours after their stimulation. 
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Synthesis and antimicrobial activity of silver nanoparticles generated with Antarctic bacteria 
broths  
1. Four new psychrophilic Antarctic bacteria have been employed in the synthesis of AgNPs. 
2. Biosynthesis of AgNPs was successful at low (4 °C) and medium (30 °C) temperatures. 
3. The diameter of AgNPs obtained depend on the bacteria and temperature used and ranged    
5-11 nm. 
4. The AgNPs obtained are excellent antimicrobials against Gram-negative and Gram-positive 
bacteria, presenting a very low IC50 >10 µg/ml. 
5. AgNPs at 4 °C are stable and active antibacterials even 10 months under light. 
 
DNA silver nanoclusters as novel nanoantibiotics  
6. DNA-stabilized AgNCs show antibacterial activity against Gram-positive and Gram-negative 
bacteria. 
7. Antibacterial activity depends on the sequence of the oligonucleotides employed.  
8. Trimers of selected sequences (Seq3), improved antibacterial activity providing an excellent 
inhibition of bacteria growth at low concentration (750 nM). 
9. ROS levels increased in the presence of DNA-AgNCs. Thus, we speculate that the antibacterial 
activity of DNA-AgNCs could be partially due to oxidative damage. 
 
Photodynamic Therapy using Photosensitizers conjugated to oligonucleotides 
10. Oligonucleotides modified with a fluorescence dye (HEX) are able to kill bacteria upon 
exposure to the proper light. The final activity can be enhanced by the addition of AgNCs.  
11. The activity of ONs-HEX seems to be better at low concentrations, were self-quenching and 
aggregation are reduced. 
 
p21 regulation with oligonucleotides conjugated to gold nanoparticles  
12. AuNPs can be used to deliver different bioactive oligonucleotides (antisense and SiRNAs), into 
cells. 
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13. This method allows the reduction at very early time points of the target protein without 
inducing cell death, as is the case in electroporation methods (like the Amaxa kit). 
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                                                                                                                                                 CONCLUSIONES 
 
Síntesis y actividad antimicrobiana de nanopartículas de plata obtenidas a partir de medio de 
bacterias de la Antártica.  
1. Cuatro nuevas bacterias psicrófilas de la Antártica han sido utilizadas en la preparación de 
AgNPs.  
2. La obtención de las AgNPs puede llevarse a cabo a distintas temperaturas (4 °C y 30 °C) . 
3. El diámetro de las AgNPs depende de la bacteria y temperatura empleadas, el cual se 
encuentra entre 5-11 nm. 
4. Las nanopartículas obtenidas han mostrado buena actividad (IC50 >10 µg/ml) contra bacterias 
Gram-negativas y positivas.  
5.  AgNPs preparadas a 4 °C mantienen su actividad tras 10 meses incubadas bajo la luz.  
 
Nanoclústeres de Plata estabilizados por ADN como nuevos nanoantibióticos.  
6. DNA-AgNCs se han mostrado activos contra bacterias Gram-positivas y negativas.   
7. La actividad antibacteriana depende de la secuencia empleada.  
8. La preparación de un trímero con la secuencia Seq-3 mejora su actividad, inhibiendo el 
crecimiento bacteriano a muy baja concentración (750 nM). 
9. La producción de ROS es  aumentada en presencia de DNA-AgNCs , lo que sugiere que la 
actividad puede deberse en parte a daño oxidativo.    
 
Terapia fotodinámica utilizando fotosensibilizadores conjugados a oligonucleótidos.  
10. Oligonucleótidos modificados con una molécula fluorescente (HEX) son capaces de eliminar 
bacterias cuando son excitados con luz. La actividad final puede verse mejorada en algunos 
casos mediante la formación de los correspondientes AgNCs. 
11. La actividad de estos sistemas parece ser mayor a baja concentración donde los efectos de 
self-quenching y agregación son menores.  
   116 
 
7 CONCLUSIONS 
Regulación de p21 con oligonucleótidos conjugados a nanopartículas de oro.  
12. Las AuNPs pueden utilizarse para transportar diferentes oligonucleótidos con actividad 
biológica a las células. 
13. Este método permite la reducción de la expresión de la proteína deseada a tiempos cortos 
con muy baja toxicidad, comparado con técnicas de electroporación (Amaxa kit). 
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                    10. SUPPLEMENTARY  
                          INFORMATION 
 SI.1.Simplified TXRF of the different AgNPs used in this study. Cell-free supernatants used in the preparations were, from A,B). 
Psychrobacter sp  (30 °C and 4 °C), C,D). A.salmonicida (30 °C and 4 °C), E,F). P.veronii (30 °C and 4 °C), G,H). Y.kristensenii       
(30 °C and 4 °C), Both peaks at 3 and 3.3 keV come from silver, while small peaks at 2.7 and 3.7 keV correspond to chloride and 
calcium respectively. 
C D
E F
G H
   
 
 
SI.2. X-Ray Diffraction pattern of AgNPs synthesis by broths of A,B). A.salmonicida (30 °C and 4 °C), C,D). P.veronii (30 °C and 
4 °C), E,F). Y.kristensenii (30 °C and 4 °C). 
0
200
400
600
800
1000
1200
1
1
0
5
2
0
9
3
1
3
4
1
7
5
2
1
6
2
5
7
2
9
8
3
3
9
3
7
1
0
4
1
1
1
4
5
1
2
4
9
1
3
5
3
1
4
5
7
1
5
6
1
1
6
6
5
1
7
6
9
1
8
7
3
1
9
7
7
2
0
8
1
2
1
8
5
2
2
8
9
2
3
9
3
2
4
9
7
2
6
0
1
2
7
0
5
2
8
0
9
2
9
1
3
In
te
n
si
ty
 (a
.u
.)
2θ (degrees)
A
0
200
400
600
800
1000
1200
1400
1600
1800
1
1
0
5
2
0
9
3
1
3
4
1
7
5
2
1
6
2
5
7
2
9
8
3
3
9
3
7
1
0
4
1
1
1
4
5
1
2
4
9
1
3
5
3
1
4
5
7
1
5
6
1
1
6
6
5
1
7
6
9
1
8
7
3
1
9
7
7
2
0
8
1
2
1
8
5
2
2
8
9
2
3
9
3
2
4
9
7
2
6
0
1
2
7
0
5
2
8
0
9
2
9
1
3
In
te
n
si
ty
 (a
.u
.)
2θ (degrees)
B
0
100
200
300
400
500
600
700
800
900
1
1
0
1
2
0
1
3
0
1
4
0
1
5
0
1
6
0
1
7
0
1
8
0
1
9
0
1
1
0
0
1
1
1
0
1
1
2
0
1
1
3
0
1
1
4
0
1
1
5
0
1
1
6
0
1
1
7
0
1
1
8
0
1
1
9
0
1
2
0
0
1
2
1
0
1
2
2
0
1
2
3
0
1
2
4
0
1
2
5
0
1
2
6
0
1
2
7
0
1
2
8
0
1
2
9
0
1
In
te
n
si
ty
 (a
.u
.)
2θ (degrees)
C
0
200
400
600
800
1000
1200
1
1
0
5
2
0
9
3
1
3
4
1
7
5
2
1
6
2
5
7
2
9
8
3
3
9
3
7
1
0
4
1
1
1
4
5
1
2
4
9
1
3
5
3
1
4
5
7
1
5
6
1
1
6
6
5
1
7
6
9
1
8
7
3
1
9
7
7
2
0
8
1
2
1
8
5
2
2
8
9
2
3
9
3
2
4
9
7
2
6
0
1
2
7
0
5
2
8
0
9
2
9
1
3
In
te
n
si
ty
 (a
.u
.)
2θ (degrees)
D
0
100
200
300
400
500
600
700
800
900
1
1
0
1
2
0
1
3
0
1
4
0
1
5
0
1
6
0
1
7
0
1
8
0
1
9
0
1
1
0
0
1
1
1
0
1
1
2
0
1
1
3
0
1
1
4
0
1
1
5
0
1
1
6
0
1
1
7
0
1
1
8
0
1
1
9
0
1
2
0
0
1
2
1
0
1
2
2
0
1
2
3
0
1
2
4
0
1
2
5
0
1
2
6
0
1
2
7
0
1
2
8
0
1
2
9
0
1
In
te
n
si
ty
 (a
.u
.)
2θ (degrees)
E
0
200
400
600
800
1000
1200
1400
1600
1
1
0
5
2
0
9
3
1
3
4
1
7
5
2
1
6
2
5
7
2
9
8
3
3
9
3
7
1
0
4
1
1
1
4
5
1
2
4
9
1
3
5
3
1
4
5
7
1
5
6
1
1
6
6
5
1
7
6
9
1
8
7
3
1
9
7
7
2
0
8
1
2
1
8
5
2
2
8
9
2
3
9
3
2
4
9
7
2
6
0
1
2
7
0
5
2
8
0
9
2
9
1
3
In
te
n
si
ty
 (a
.u
.)
2θ (degrees)
F
